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Imaging: System and Algorithm Developments 
Hamed Vavadi, PhD 
University of Connecticut, 2017 
According to the World Health Organization, breast cancer is the most common cancer among 
women worldwide, claiming lives of hundreds of thousands of women each year. Mammography, 
ultrasound (US) and magnetic resonance imaging (MRI) are widely used to detect and diagnose 
breast lesions and each of them have some disadvantages which motivates researchers to find a 
new and high sensitive imaging method. Diffuse optical tomography (DOT) is a noninvasive 
functional imaging modality that utilizes near-infrared (NIR) light to probe tissue optical 
properties. Minimal light absorption in the NIR spectrum allows for several centimeters of light 
penetration in soft tissue.  NIR is sensitive to hemoglobin which is directly related to tumor 
angiogenesis. If multiple wavelengths are used, it can probe tumor oxygen saturation.  However, 
DOT has drawbacks on location uncertainty and low light quantification accuracy due to tissue 
scattering of NIR light.  Ultrasound (US)-guided Diffuse Optical Tomography has overcome these 
problems. 
The overall objective of my research is to move US-guided DOT one step closer from a research 
imaging modality to a commercial prototype for future wide use in clinics. To achieve this goal, I 
have overcome several challenges in both imaging hardware and software.  In this Dissertation, I 
will discuss the progress we have made on development of two generations of US-guided DOT 
systems along with the software improvements.  The developed systems have been improved in 
terms of robustness, stability, clinical safety and standards and user friendliness. In terms of 
software and algorithm development, automated methods for data selection, outlier removal and 
reference and perturbation filtering are presented. These methods have improved the robustness of 
the technique and increased speed of image formation by eliminating the need for an expert to 
perform data preprocessing and data selection.  Phantom and clinical experimental results will be 
demonstrated to evaluate the performance of the developed systems and algorithms.
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1. Introduction to Breast 
Imaging  
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1.1. Introduction 
Medical imaging is a wide expanding field of development and research. Several methods and 
modalities for medical imaging have been developed during last century and they have found wide 
application in disease screening, diagnosis, and treatment monitoring. While each of the currently 
used conventional imaging has their strength and drawbacks, the urge to develop a new imaging 
technique, which could address current needs in medical application to improve human health, is 
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being felt more than ever. One of the promising ideas for next-generation medical imaging devices 
is optical imaging. While several methods of optical imaging with different wavelength sub-bands 
are currently under investigation, I am going to focus on the use of near infra-red light in optical 
imaging. The infrared light has several interesting characteristics such as good depth of penetration 
inside the tissue and sensitivity to hemoglobin. In this dissertation, I will specifically talk about 
near infra-red diffuse optical tomography method and the steps I took to move this modality one 
step closer to use widely in the clinical setting for breast cancer detection. 
The dissertation is structured as below: 
Chapter 1 gives a brief introduction to the background of the medical imaging and breast 
cancer. 
Chapter 2 is discussing the principles of near infra-red diffuse optical tomography and its 
expansion to ultrasound-guided diffuse optical tomography. 
  Chapter 3 is focused on the development of the third generation of the ultrasound-guided 
diffuse optical tomography system and the results of clinical studies which have been done with 
that system. 
Chapter 4 is along the path of chapter 3 and discuss the development of the fourth 
generation of Ultrasound-guided DOT system. In that chapter, we’ll discuss the results of phantom 
experiments which have been done with this system. 
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In chapter 5 we’ll study the effect of reference heterogeneity on the reconstructed DOT 
absorption map and introduce a smoothing method to reduce the effect of the reference 
heterogeneity in the reconstructed absorption map. 
Chapter 6 is dedicated to the algorithm developments for improving the robustness of 
diffuse optical tomography technique for breast cancer detection. This algorithm specifically 
focuses on using multiple references and a perturbation filtering method to eliminate measurement 
outliers. This algorithm makes the process of data preprocessing automated by forming a robust 
reference measurement to eliminate the need for an expert user in data processing and improve the 
accuracy of US-guided DOT. 
Finally, in chapter 7, we will summarize the first 6 chapters and make a conclusion about 
the progress we have made and provide ideas for the next step of system and algorithm 
development. 
With this short introduction, we will continue to review the basic concepts which are going to 
be used in this Ph.D. Dissertation. 
1.2. History of Medical Imaging 
Wilhelm Röntgen, a physics professor discovered the x-rays in 1895 and it has been the start point 
of medical imaging. Different density of tissue results in different absorption of the X-ray passing 
through the tissue and results in a different number of x-ray photons reaching the film or camera 
detector on the other side of the tissue. This concept of utilizing different absorption of the X-Ray 
to map the density of the underlying tissue was a great breakthrough at the time and it 
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revolutionized the field of medical science and diagnosis [1]. Although the x-ray was a great 
breakthrough in the field of diagnostic sciences, scientists were not aware of the dangers of 
ionizing radiation of x-ray. Besides that, while x-ray has a great ability to differentiate soft tissue 
from the bones and hard objects, it lacked sensitivity to distinguish different soft tissues. 
The second breakthrough in medical imaging happened in 1960’s when the principles of 
ultrasonic beams have been utilized for medical imaging and the simple 2D ultrasound imaging 
devices were developed. Since then, this technology was expanded and several devices with 
multiple applications including, Sonographer, Echocardiography, Doppler blood flow 
measurements, and focused ultrasound have been developed. Besides all the improvements, the 
concept of ultrasound remained fixed. The ultrasound transducer transmits high-frequency 
ultrasound waves into a body and the pulses or waves penetrate the body and bounce back from 
the tissue. The bounced back ultrasound waves are detected by the transducer and convert to 
electrical signals. The time delay of each detected ultrasound pulse represents the path this pulse 
has traveled inside the tissue and the intensity of it represent the mechanical properties of the tissue 
it passed through and bounced back from. This information is used to form an image of the 
mechanical properties of the tissue. Since ultrasound had no known adverse effect on the patients, 
it is one of the safest and popular imaging technique [2]. 
Computed tomography was invented in 1970’s.  This technique uses computer-processed 
X-rays in different angles to form tomographic slices of the body. As it could provide tomographic 
slices, it improved the insight into the pathogenesis of the body and diagnosis. The early generation 
of X-ray imaging was slow due to the computational cost of this technique, but now a day, by 
developments in computer processing a CT scanner can reconstruct a tomographic image almost 
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instantly [3]. The two contributing inventors of this technology have received a Nobel Prize in 
medicine. 
At the same time when the computed tomography was invented, Raymond Damadian 
discovered the difference of the nuclear magnetic relaxation times between the different tissues. 
As it was a promising discovery, several researchers all around the world worked around 20 years 
to develop this concept into Magnetic Resonance Imaging (MRI) technology. MRI sends strong 
magnetic waves through the body which causes the alignment of the protons. While these protons 
move back into their original positions, they radiate waves which are detected by the detector. 
These different radiations of particles inside the body are then used to form an image. Currently, 
MRI is widely used for diagnostic applications by providing very good differentiation between 
different soft tissues [4]. 
 
1.3. Breast Cancer 
Breast, lung, and colorectum cancers are the three most commonly diagnosed cancers, representing 
one-half of all cancer cases among women. Breast cancer alone is expected to account for 29% all 
new cancer diagnoses in women in 2017. In average, one out of 8 American women will develop 
breast cancer over the course of their lifetime. Based on the statistics from American cancer 
society, right now there are around 2.8 million women with a history of breast cancer in the united 
states. This number includes women currently being treated and women who have completed 
receiving treatment. It has been estimated that in united states in 2017, 255,180 new cases of 
invasive breast cancer along with 63,410 new cases of non-invasive breast cancer will be detected. 
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Despite the decrease in death rates for breast cancer since 1989, it is estimated that unfortunately 
about 40,610 women will die from breast cancer in 2017 [12,13]. 
In breast cancer cells in the breast start to grow out of control and form a tumor. If the tumor cells 
have the potential to invade surrounding tissues or spread to distant areas of the body the tumor is 
called Malignant. Here we should note that most of the breast lesions do not invade surrounding 
tissue or spread to the other part of the body. These kinds of lesions are benign lesions. 
Although benign lesions are abnormally grown inside the breast, unlike the malignant lesions they 
are not life-threatening for the patient as they are not invasive. 
 
 
Figure 1.1.  Normal breast tissue (ref. National cancer institute, [5,6]) 
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1.4. Breast Cancer Diagnosis and 
Treatment Monitoring 
Different imaging methods have been used for both detection and treatment monitoring phase of 
breast cancer. Conventional imaging methods such as mammography, ultrasound imaging (US), 
and magnetic resonance imaging (MRI), are the most commonly used methods to detect and 
diagnose breast cancer. Mammography as the most clinically used imaging modality for breast 
cancer diagnosis has relatively low sensitivity in early cancer diagnosis and weak sensitivity in 
women with dense breasts [14]. ultrasound demonstrates robust results in detecting breast cancer 
with comparable rate to mammography, but it still lacks sensitivity and specificity which results 
in several false positive cases [15]. MRI, on the other hand, shows a significantly higher sensitivity 
in breast cancer detection and diagnosis compared to US and mammogram, but the high costs of 
MRI and relatively low cancer detection rate in the general screening population limits its 
applicability as a screening and monitoring tool in several situations [14]. In the treatment phase 
of breast cancer, different modalities have been used to monitor the patient response to the 
neoadjuvant chemotherapy, while a method that can provide accurate results at early stages of 
treatment is yet to be found. On one hand, US and mammography, are two highly used methods 
to monitor the response of patients to neoadjuvant chemotherapy and they just show moderate 
sensitivity in the assessment of tumor response. On the other hand, dynamic contrast-enhanced 
MRI and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed 
tomography (PET/CT) can predict the presence of residual tumor after completion of each NAC 
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which could decrease the patient additional exposure to ineffective and toxic treatments [15-17]. 
Although these methods have shown the ability in early identification of patients not responding 
to neoadjuvant chemotherapy, their equipment is bulky and expensive, and they require the 
injection of contrast agents which prevent them from being used repeatedly for monitoring patients 
during treatment. 
Optical imaging using near infra-red light has shown promising results in detection and 
diagnosis of breast cancer and this technique will be discussed in chapter two with more details.  
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2.1. Diffuse Optical Tomography 
In last decades, the application of near infra-red (NIR) light for imaging has been under intense 
investigation. NIR diffuse optical tomography (DOT) is a noninvasive imaging technique that uses 
near infra-red light to assess optical properties of tissue. Because of the minimal light absorption 
of water at the near infra-red wavelength range (∼700 to 900 nm), the light will penetrate 
sufficiently in tissue to acquire tomographic images [1-4]. Besides the low absorption of water at 
13 
 
near infra-red, this wavelength range is also sensitive to oxygenated and deoxygenated hemoglobin 
(HbO2 and Hb) [5,6]. Oxygenated and deoxygenated hemoglobin are two important chromophores 
found in the cancer lesions, and are related to tumor angiogenesis and cell activity. This sensitivity 
to oxy and deoxyhemoglobin results in several important applications for this technology such as 
brain activity monitoring and cancer detection. This sensitivity also resulted in promising results 
in assessing breast cancer. Besides that, DOT also has demonstrated great potential in the 
assessment of tumor vasculature response to neoadjuvant chemotherapy.  DOT systems are 
portable, require no contrast agents, and have a low cost which makes them an ideal alternative for 
currently used modality for breast cancer diagnosis and monitoring in clinical settings. Besides 
aforementioned benefits, DOT can be used as a complimentary breast imaging method along with, 
ultrasound, X-ray mammography, and magnetic resonance imaging (MRI) in the diagnosis of 
breast cancer as well as treatment monitoring. Several research groups are investigating different 
techniques of diffuse optical tomography. In general, these researchers can be divided into 3 
different groups, as time domain, frequency domain, and continuous wave DOT. Some groups, 
including our group, combine DOT imaging modality with another modality, such as ultrasound 
or MRI. We focused on frequency domain diffuse optical tomography systems and we combined 
it with ultrasound imaging method. We have studied the feasibility of using US-guided NIR 
imaging technique for detecting breast cancer as well as monitoring patients who were undergoing 
Neo-adjuvant chemotherapy [7]. 
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2.2. Ultrasound-guided DOT  
Ultrasound-guided diffuse optical tomography (US-guided DOT) uses ultrasound as a guidance to 
localize the lesion and improve the tissue illumination and reconstruction results. In our approach 
of US-guided DOT, we acquire 3 different measurements for each experiment. The very first 
measurements are from a known intralipid solution which will be used to calibrate the rest of the 
measurements from the patients. We then use ultrasound to localize the lesion and acquire multiple 
sets of measurements from the lesion site.  Next, we move the probe to the contralateral breast to 
acquire multiple reference measurements. Then these measurements are used to reconstruct image 
as is described here.  
First, the Intralipid datasets are loaded to calculate the system parameters for calibration, 
then the contralateral normal breast is measured, and data processed to estimate background tissue 
optical properties. These properties are used to compute a weight matrix for image reconstruction.  
The perturbation or scattered field is calculated as the difference between the reference data and 
the lesion data. Finally, by solving the inverse problem, the absorption distribution inside the 
medium can be estimated. 
Born approximation is used to relate the scattered field (Usc) measured at the probe surface 
to absorption variations in each volume element within the sample. In the Born approximation, the 
scattered field measured at source (s) and detector (d) is related to the weight W and the absorption 
change, a

,  inside the medium. By digitizing the imaging volume into N voxels, the matrix form 
of image reconstruction is given by  
                                                        
    11 ][   NaNMMsd WU                                             (1) 
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where M is the total number of source-detector pairs, and W is the weight matrix, which describes 
the distribution of diffuse wave in the homogenous medium and characterizes the measurement 
sensitivity to different voxels inside the medium.  To solve the unknown absorption distribution, 
the inverse problem is formulated as an optimization problem as: , where  
is the Euclidean norm. The conjugate gradient method is used to solve the inverse problem.  
Because the total number of source-detector pairs (M) on the probe is much smaller than the total 
number of voxels in the medium, the inverse problem is underdetermined and ill-posed. However, 
ultrasound is excellent in providing the information about the target depth and approximate size of 
target. We have integrated the target information from ultrasound and developed the dual-mesh 
imaging reconstruction algorithm.  Briefly, the entire tissue volume is segmented based on initial 
co-registered ultrasound measurements into a lesion region L and a background region B. The 
image reconstruction matrix is given as: 
                    
    11 ],[,   N
T
BLNMBLMsd
MMWWU
                                   (2) 
where WL and WB are weight matrices for lesion and background regions, respectively, and [ML] 
= [∫1L Δµa (r′) d3 r′, ...... ∫NL Δµa (r′) d3 r′ and [MB] = [∫1B Δµa (r′) d3 r′, ...... ∫NB Δµa (r′) d3 r′) are 
total absorption distributions of lesion and background regions, respectively.  The absorption 
distributions can be obtained by dividing the total absorption with the voxel sizes of lesion and 
background, respectively.   
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2.3. DOT for Neoadjuvant Chemotherapy 
In the past decade, optical tomography and optical spectroscopy using near-infrared (NIR) diffused 
light has demonstrated great potential in the assessment of tumor vasculature and oxygen 
consumption responses to NAC [8-20].  The NIR technique utilizes intrinsic hemoglobin contrast, 
which is directly related to tumor angiogenesis, a key process required for tumor growth and 
metastasis.  When multiple wavelengths are used, the optical absorptions at those wavelengths can 
be measured, and the proportions of oxygenated hemoglobin (oxyHb) and deoxygenated 
hemoglobin (deoxy-Hb) can be calculated, which are correlated with tumor oxygen metabolism 
and treatment resistance.   
Optical systems are low cost and safe with no ionizing radiation and are ideally suited for 
repeated use at clinical settings. Recently, significant progress has been made on early prediction 
of NAC using Optical spectroscopy or tomography. In a study using NIR spectroscopy, 11 patients 
were monitored pretreatment and within one week of initial treatment [8]. DeoxyHb decreased 
within the first week in pathologically confirmed responders, whereas no significant change was 
found in non-responders. In addition, the measured total hemoglobin (tHb) decreased in all 
responders.  Another study of 23 patients reported by the same group found a statistically 
significant increase, or flare, in oxyHb in responders on day 1, in contrast with a lack of flare or 
decrease in oxyHb noted on day 1 in non-responders [13]. An additional study reported by Ueda 
et al has shown that the pretreatment or baseline tumor oxygen saturation SO2 = oxyHb/tHb×100 
correlates with the pathological complete response for patients undergoing NAC [16]. Recently, a 
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study reported by Jiang et al have shown that pretreatment tHb measured by Diffuse Optical 
Spectroscopic Tomographic imaging predicts breast tumor response to NAC [19]. 
We previously have developed a dual-modality approach by using the co-registered US to 
guide light illumination, reception and also image reconstruction [10,14, 20, 21].  This approach 
overcomes the problem of poor lesion localization of light due to optical scattering and improves 
reconstruction accuracy of lesions by using a priori lesion depth and size information obtained 
from US images.  Recently, a multi-year study using US-guided Optical Tomography has 
completed.   A total of 32 patients who were undergoing NAC were assessed pretreatment, at the 
end of every treatment cycle, and before surgery [15].  The significant findings from this group of 
patients are: 1) pretreatment tumor hemoglobin content (tHb, oxy- and deoxy-hemoglobin) 
predicts patient pathological response to NAC, 2) the percentage of tHb changes (%tHb) 
normalized to the pretreatment level can be used to further identify responders from non-
responders at the early treatment cycles (2 to 3 weeks after the initiation of NAC), 3) combining 
widely used tumor pathologic variables and receptor status with hemoglobin functional parameters 
obtained before the initiation of NAC, substantially improved prediction  can be achieved using a  
logistic prediction model [19].  
To validate these results at multiple sites, we have developed third and fourth generation 
of US-guided NIR diffuse optical tomography (DOT) systems for clinical experiments. The new 
systems are compact, portable and robust in clinical operation. In the next two chapters, I focus on 
the development of the third and fourth generation of the US-guided NIR diffuse optical 
tomography (DOT) systems. The results of the clinical studies with the third generation of the 
system are presented in chapter three, and the phantom results of the fourth generation of the 
system are presented in chapter four. 
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3.1. Abstract 
In this chapter, I’ll describe the development of the third generation of ultrasound guided diffuse 
optical tomography (US-DOT) system and then present the US-DOT system progress of utilizing 
ultrasound-guided diffuse optical tomography for predicting and monitoring neoadjuvant 
chemotherapy outcomes of breast cancer patients. The clinical results acquired with the developed 
prototype for the first patient will be discussed in this chapter. The patients have been closely 
monitored before NAC, at day 2, day 8, end of first three cycles of NAC and before surgery and 
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the imaging result is given as an example to demonstrate the potential of US-guided DOT 
technique and the performance of our system in clinical setting. 
 
3.2. Introduction 
Neoadjuvant chemotherapy (NAC) is increasingly used treatment to prepare patients with locally 
advanced breast cancers for surgery. The patient may receive neoadjuvant chemotherapy for breast 
cancer to shrink a tumor that is inoperable in its current state, so it can be surgically removed. 
Neoadjuvant therapy is also used for the patients whose tumor can be removed by mastectomy, to 
shrink the tumor enough to allow breast-conserving surgery. If a tumor does not respond (shrink) 
or continues to grow during neoadjuvant chemotherapy, the doctor may stop treatment and try 
another type of chemotherapy or perform surgery instead, depending on the stage of cancer. 
The role of imaging for treated patients with neoadjuvant therapy for breast cancer is not only 
to evaluate the therapeutic response in terms of tumor shrinkage but also to predict the histological 
response to chemotherapy, which is correlated to survival rate. Surgery and histopathological 
analysis after neoadjuvant therapy allow for an objective assessment of the accuracy of imaging 
techniques in evaluating response. Different modalities have been used to differentiate between 
patients who respond and who don't respond to NAC; while a method which can provide accurate 
results at early stages of treatment is yet to be fully developed. 
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Physical examination is providing mediocre accuracy for assessing the response of locally 
advanced breast cancer to NAC treatment. It could be because of either palpation of a fibrotic and 
necrotic mass which may mimic a residual tumor mass or due to the resolution of post-biopsy 
phenomena such as hemorrhage and edema. Mammography and ultrasound are the most used 
methods for the initial staging and the assessment of tumor response to neoadjuvant 
chemotherapies. These methods are aiming the comparative measurement of the tumoral volume 
and the accuracy of them highly depends on the contrast between the tumor and the surrounding 
normal tissue. MRI allows morphological analysis of tumors and kinetic study of the contrast 
enhancement reflecting the richness of the vascularization, which could provide early 
identification of nonresponders. This method can predict the presence of residual tumor after 
completion of each NAC which could decrease the patient additional exposure to ineffective and 
toxic treatments. 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed 
tomography (PET/CT) have been reported to show good performance in excluding distant 
metastases prior to neoadjuvant chemotherapy (NAC) treatment. The usage of MRI and PET/CT 
are not suitable for repetitive use, because the equipment is bulky and expensive, and PET/CT 
require the injection of contrast agents as well. These constraints prevent them from being used 
repeatedly for monitoring patients during treatment.   
Diffuse optical tomography (DOT) in the near-infrared (NIR) spectrum provides a unique 
approach for functional diagnostic imaging. This imaging technique can detect endogenous 
absorbers, and also determine the hemoglobin concentration and oxygen saturation. Near-infrared 
diffuse optical tomography (NIR-DOT) systems are portable, low cost, non-ionizing and require 
no contrast agents, which make them an ideal alternative for repeated use in clinical settings. Near-
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infrared (NIR) diffuse optical tomography also has demonstrated great potential in the assessment 
of tumor vasculature response to neoadjuvant chemotherapy.  
 
3.3. Previous Systems 
In the past, we have developed two frequency domain DOT prototype systems which were used 
with commercial ultrasound systems in clinical studies.  The first prototype system consisted of 
12 pairs of laser diodes of wavelength 780 and 830 nm and eight parallel channel photomultiplier 
tube (PMT) detectors [1].  Each pair of dual-wavelength laser diodes delivered the light through 
an optical coupler to a hand-held probe of 10 cm diameter and all parallel detectors received the 
reflected light simultaneously via optical light guides mounted on the probe.   The laser diodes 
were modulated at 140MHz and the detected signals were mixed with the 140.02 MHz reference 
signal and were further amplified and filtered at 20 KHz for processing.  A commercial ultrasound 
array transducer was located in the middle of the probe for guiding the localization of breast lesions 
and image reconstruction.  
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Figure.3.1.  First generation of Ultrasound guided DOT system along with custom made 64 channels 
ultrasound system 
 
The second prototype system consisted of four laser didoes of wavelengths 740, 780, 808 
and 830nm which were sequentially switched by 4 x 1 and 1 x 9 optical switches to 9 source 
positions on the hand-held probe [2].  The detection included 10 photomultiplier tube (PMT) 
detectors and associated parallel electronics.  The reflected light was coupled to the detectors via 
optical light guides mounted on the probe.  The initial promising clinical results obtained from 
these prototype systems have been reported in several publications [2-7]. 
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Han  
Figure.3.2.  Second generation of Ultrasound guided DOT system along with a commercial ultrasound system 
 
In both prototypes, a pair of National Instrument Data Acquisition (DAQ) boards and a desk 
top PC were used for data acquisition and display which has contributed to the bulkiness of the 
system in clinical studies.  
 
3.4. Third-Gen of NIR-DOT system  
In our early prototypes, the two National Instrument Data Acquisition (DAQ) boards and cables 
which connect DAQ boards inside a desktop PC to the NIR system have contributed to the cost 
and significant bulkiness of the system because two rigid RF shielding cables have to be used to 
reduce ~20KHz interference signals generated from beating of two high frequency signals from 
Hand-held probe 
NIR System 
US System 
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source and detection systems.  We have replaced the two NI DAQ boards with a custom-designed 
compact on-board DAQ board which will be housed inside the detection.   
The DAQ consists of two AD7609 ICs (Analog Device), one SPARTAN 3E FPGA and 2MB 
SRAM.  AD7609 has 8 simultaneously differential input channels with analog input range of ±10V 
which is ideal to handle a larger dynamic range of diffused light signals received from near and 
far source-detector pairs.  The sampling speed of AD7609 is 200kHz and resolution is 18 bits.  The 
SPARTAN 3E FPGA features 18-bit multipliers, 72Kbits of fast dual-port block RAM, and 
500MHz+ operation.  It has USB 2 full-speed port for FPGA configuration and data transfers to a 
lap top PC.  The 2MB 16 SRAM is designed to buffer the data for one set of data acquired from 
all wavelengths and all sources and detectors. Figure 3.3 illustrate the block diagram of the FPGA 
based data acquisition board. 
 
Figure.3.3. Block diagram of data acquisition board 
ADC1 
ADC2 
FPGA chip 
SPARTAN 3E  
EZ USB 
chip 
E
E
P
R
O
M
 
4
M
B
 
E
E
P
R
O
M
 
2
M
B
 
S
R
A
M
 
Optical switches Control 
Input channels 1-8 
Input channels 9-16 
28 
 
 
Figure 3.4. Final manufactured FPGA based data acquisition board 
 
The SPARTAN 3E FPGA has a USB 2 full-speed port for FPGA configuration and data transfers 
to the laptop PC.  Beside data acquisition, the FPGA is used to control the two optical switches of 
4 x 1 and 1 x 9 for sequentially selecting one of the four wavelengths (740, 780, 808, 830nm) and 
one of the 9 source positions on the hand-held probe. PMT detectors and parallel electronic 
channels were used for parallel data acquisition 
One of the other improvements in the third generation of our US-guided DOT system is 
the increase in the number of detection channels from 10 to 14. Besides that, a new layout of the 
electronics and optical components was designed to make the system as compact as possible 
without sacrificing the system heat dissipation, robustness, and signal to noise ratio. 
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Figure 3.5.  shows the third prototype system dimensions (60 cm x 36 cm x 48 cm) and layouts. 
 
Figure 3.5. The layout of the optimized third gen DOT system 
 
Our hybrid probe used in previous clinical studies was not robust.  A commercial US probe 
was plugged into the open slot in the middle of the hybrid probe before each patient study and an 
engineer operator had to hold the bundle of optical fibers and the US probe tightly together during 
the study.  Any significant bending of optical fibers during hand-held operation can produce bad 
channel (either detector or source) data with lower signal due to light loss.  Often, we have had to 
manually remove these data during off-line processing.  For the improved prototype, we use the 
following design to improve the hybrid probe for robust and user-friendly operation. As shown in 
Figure 3.6 (a), the US transducer will be inserted into the central slot of the probe base and firmly 
locked to the probe base by two spring plungers which push the transducer down at its shoulder. 
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After US transducer is connected, the probe cover which is used to cover and protect the optical 
fibers and US transducer can lock in with the probe. The final probe will be free of hand and fiber 
contact and easy to hold and operate as shown in Figure 3.6. (b).  
 
 
 Figure 3.6. (a) The improved hybrid probe design; (b) Probe cover and probe. 
 
The intralipid phantom data were collected using the improved NIR system. Figure 3.7(a) shows 
the amplitude vs. source-detector distance at 830nm, where amplitude is plotted in log(r2*I(r)). 
The amplitude shows good linearity, and the dynamic range of system can reach to 60 dB. Figure 
3.7. (b) shows the phase vs. source-detector distance.   
(a) (b) 
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Figure 3.7. Intralipid phantom experiment data from the improved NIR system. (a) log(r2*I(r)) vs. source-
detector distance; (b) Phase vs. source-detector distance 
 
Figure 3.8 shows the block diagram of the optimized US-Guided NIR DOT system. Besides using 
a faster FPGA based data acquisition, by optimizing electronic components we were able increase 
number of detection channels from 10 to 14 in this new prototype.  A custom made optical 
decoupling board have been designed to decouple any noise transfer between source and detector 
boxes and increase signal to noise ratio. 
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Figure. 3.8. Block diagram of the third generation of the ultrasound guided DOT system. 
 
After described optimization steps, three prototypes of the third-gen ultrasound guided DOT 
system were developed and moved to three different hospitals for clinical studies. 
Figure 3.9 shows a photograph of the upgraded NIR system used at the UCONN Health Center. A 
commercial ultrasound transducer can be readily plugged into the hand-held probe for 
simultaneous ultrasound and optical imaging.   
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Figure 3.9. The upgraded NIR system currently used at the UCONN Health Center. The commercial 
ultrasound transducer is readily plugged into the combined probe which houses all source and detector fibers 
for light delivery and collection.  The co-registered ultrasound images are captured by a video capture card 
and are used to guide the light illumination and optical imaging reconstruction.   
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3.5. Clinical Results 
To validate the performance of the developed system in monitoring patients undergoing 
neoadjuvant chemotherapy, we have done a clinical study with three systems at three different 
hospitals. The study had IRB approval for all three sites and all patients consented to their 
participation. In this section, we are going to describe the clinical results obtained from the first 
patient.   The first patient entered the new trial in March 2014 was a 37 years old woman with an 
invasive mammary carcinoma of mixed lobular and ductal features.  The histological grade and 
nuclear grade were 3, and mitotic counts per 10 field high magnification were 9 and the 
Nottingham score was 8 out of 9.  The receptor status was ER positive, PR positive and HER2 
positive.  The pre-treatment MRI image, co-registered ultrasound image, and the corresponding 
DOT total hemoglobin map are given in Figure 3.10 (a-c).    
The total hemoglobin map is obtained in 7 slices from left to right and top to bottom 
corresponding to depths of 0.5 cm to 3.5 cm from the skin surface to the chest wall.   Each slide is 
given in x-y spatial dimensions of 9 x 9 cm.  The largest diameter of the tumor measured from 
MRI images was 3.6 cm, measured from US images was 2.5 cm.  The total hemoglobin distribution 
provides functional information of tumor angiogenesis distribution and also quantitative levels.  
The tumor vascular distribution is mainly distributed at the periphery of the mass which is often 
seen in aggressive high-grade tumors.  Quantitatively, the tHb level measured from the average 
maximum of several tHb images at the tumor site was 81.02 mol/L.   The patient was treated with 
dual HER2 blockade of trastuzumab and pertuzumab for six cycles of total 18 weeks.  The post-
treatment MRI image, US, and DOT total hemoglobin map are given in Figure 3.10 (d-f).  There 
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was no residual tumor seen in MRI images.  The ultrasound image revealed a smaller mass which 
can be identified by the metal clip and total hemoglobin map revealed no vascular contrast.  The 
final surgery report revealed a grossly identified mass of 5.5 cm at the location of 10-2 o’clock. 
Microscopically there were scattered tumor cells of ductal and lobular features within the scar 
tissue.  The largest residual focus measured 1.25 mm.  The Miller Payne grade was 4.  
To assess the early changes during NAC, we have monitored the patient at day 2, day 8, 
end of cycle 1, 2 and 3.  Figure 3.11 shows five sets of co-registered US images and total 
hemoglobin maps obtained at these time points and Figure 3.12 is the quantitative total hemoglobin 
level calculated from average maximum tHb levels with the average taken from several tHb images 
at the tumor site at each time point.  It is interesting to note that at day 2, the periphery distribution 
of total hemoglobin is similar to the pre-treatment pattern, however, 24% higher total hemoglobin 
content was observed which may due to initial tumor vascular response to NAC treatment.  At day 
8, the total hemoglobin map has changed to more centralized distribution, but the level is still 12% 
higher than that at the pre-treatment level.  At the end of cycle 1, the total hemoglobin level 
dropped to 73% of the pre-treatment level.  At the end of cycles 2 and 3, the tHb is in the 
background level with no vascular contrast.   
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Figure 3.10.   Patient with an invasive mammary carcinoma located at 2 o’clock position of her left breast.  
Baseline or pre-treatment MRI image (a), ultrasound image (b) and total hemoglobin map (c).   Total 
hemoglobin map revealed periphery distribution which is often seen in aggressive carcinomas.   Post-treatment 
MRI image (d), ultrasound image (e), and total hemoglobin map (f).  MRI indicated no residual tumor and 
total hemoglobin map showed no vascular contrast.  The total hemoglobin map is obtained in 7 slices from left 
to right and top to bottom corresponding to depths of 0.5 cm to 3.5 cm from skin surface to chest wall.   Each 
slide is given in x-y spatial dimensions of 9 x 9 cm. 
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Figure 
3.11.  Co-registered US images and total hemoglobin maps obtained at five time points. Day 2, 8 and cycle 1 
US images are zoomed into the depth range of 0 to 4 cm while Cycle 2 and 3 US images are zoomed in to the 
range of 0 to 2.5 cm to better visualize the tumor. 
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 Figure 3.12.  Quantitative total hemoglobin level calculated from average maximum tHb  levels with the 
average taken from several tHb images at the tumor site at each time point. 
 
3.6. Summary 
In summary, we have designed and constructed an upgraded frequency domain diffuse optical 
tomography system for robust and reliable clinical operation at multiple clinical sites. The probe 
can be easily adapted to any commercial ultrasound probe and the system is compact in size.  Three 
prototypes of the system were developed and used in three different hospitals. The systems have 
been used for assessing neoadjuvant chemotherapy response of breast cancer patients and the 
results are presented in the following sections. The results of one patients has been presented here 
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and it shows promising results in prediction of patient’s response to neoadjuvant chemotherapy as 
early as first cycle of chemotherapy. These 3 systems in three hospitals have been continued to be 
used for clinical studies and the results has been submitted to the journal of clinical cancer research. 
The results presented in this chapter have been published in multiple journals and conference 
proceeding as listed in the reference [8-11] 
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4.1. Abstract 
Based on the statistics from World Health Organization, breast cancer is the most common cancer 
among women worldwide, claiming the lives of hundreds of thousands of women each year. Near-
infrared diffuse optical tomography (DOT) has demonstrated a great potential as an adjunct 
modality for differentiation of malignant and benign breast lesions and for monitoring treatment 
response in patients with locally advanced breast cancers. The path toward commercialization of 
DOT techniques depends upon the improvement of robustness and user-friendliness of this 
technique in hardware and software. In the past, our group has developed frequency domain 
44 
 
prototype systems which were used in several clinical studies. In this study, we introduce our 
recently developed US-guided DOT system which is being improved in terms of size, robustness, 
and user-friendliness by several custom electronics and improved mechanical design. The new 
system benefits from a new user interface with includes automated data selection, outlier removal, 
and lesion boundary detection as well as a new calibration method based on the depth and size of 
the lesion detected from the ultrasound image. With all these improvements, our new system is 
more robust and accurate which is one step closer to commercialization and widespread use of this 
technology in clinical settings. This system is aimed to be used by minimally trained user in the 
clinical settings with robust performance. The system performance has been tested with several 
phantom experiments and the results show decent accuracy in terms of reconstructed absorption 
as well as strong sensitivity in terms of oxygen saturation. The system was moved to a hospital 
and was used in a clinical study to monitor patients undergoing neoadjuvant chemotherapy and the 
results are presented. 
 
4.2. Introduction 
Breast cancer is the most common cancer among women and is expected to account for 29% all 
new cancer diagnoses in women in 2017. Based on the statistics from American cancer society, 
there are around 2.8 million women with a history of breast cancer in the United States (US). This 
number includes women currently being treated and women who have completed treatment. In 
2017, 255,180 new cases of invasive breast cancer along with 63,410 new cases of non-invasive 
breast cancer will be detected in US. Despite the decrease in death rates for breast cancer since 
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1989, it is estimated that about 40,610 women in the U.S. will die in 2017 from breast cancer [1,2]. 
Treatment for many breast cancer patients starts with preoperative or neoadjuvant therapy, which 
includes chemotherapy, targeted therapy or hormone therapy to shrink the size of the lesion and 
control the growth of the tumor before breast surgery. Neoadjuvant chemotherapy and hormone 
therapy drugs are mostly same as those used after surgery (adjuvant therapy) and can shrink a 
larger tumor enough so that lumpectomy plus radiation therapy becomes an alternative option to 
mastectomy. Patients are usually assessed during neoadjuvant therapy on response in case of tumor 
progression [3]. 
Different imaging methods have been used for both detection and treatment monitoring of 
breast cancer. Conventional imaging methods such as Mammography, ultrasound imaging (US), 
and magnetic resonance imaging (MRI), are the most commonly used methods for breast cancer 
diagnosis. Mammography as the most clinically used imaging modality for breast cancer screening 
and diagnosis has relatively low sensitivity in early cancer diagnosis especially low sensitivity in 
women with dense breasts [4]. US demonstrates robust results in detecting breast cancer with 
comparable rate to mammography, but it still lacks sensitivity and specificity [5]. MRI, on the 
other hand, shows a significantly higher sensitivity in breast cancer detection and diagnosis 
compared to US and mammogram, but the high costs of MRI and low cancer detection rate in the 
general screening population limits its applicability as a screening and monitoring tool [4]. In the 
treatment phase of breast cancer, different modalities have been used to monitor the patient 
response to the neo-adjuvant therapy, while a method which can provide accurate results at early 
stages of treatment is yet to be found. On one hand, US and mammography, are two highly used 
methods to monitor the response of patients to Neo-adjuvant therapy and they just show moderate 
sensitivity in the assessment of tumor response. On the other hand, dynamic contrast-enhanced 
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MRI and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed 
tomography (PET/CT) can predict the presence of residual tumor after completion of each NAC 
which could decrease the patient additional exposure to ineffective and toxic treatments [4-6]. 
Although these methods have shown the ability in early identification of nonresponses, their 
equipment is bulky and expensive, and they require the injection of contrast agents which prevent 
them from being used repeatedly for monitoring patients during treatment. 
Near-infrared (NIR) diffuse optical tomography (DOT) is a noninvasive imaging technique 
that uses near-infrared light to assess optical properties of tissue. Because of the minimal light 
absorption of water at the near infra-red wavelength range (∼700 to 900 nm), the light will 
penetrate sufficiently in tissue to acquire tomographic images. Besides the low absorption of water 
at near infra-red wavelength range, this wavelength range is also sensitive to oxygenated and 
deoxygenated hemoglobin (HbO2 and Hb) [7-8]. DOT has shown promising results in the initial 
assessing breast cancer because of its sensitivity to oxygenated and deoxygenated hemoglobin. 
Besides that, DOT also has demonstrated great potential in the assessment of tumor vasculature 
response to neoadjuvant chemotherapy.  DOT systems are usually portable, require no contrast 
agents, and have relatively low cost. Although these characteristics of DOT systems should make 
them an ideal alternative for currently used modality for breast cancer diagnosis and monitoring 
in clinical settings, but the low spatial resolution and lesion location uncertainty caused by intense 
light scattering in soft tissue limits the wide use of this technology in the clinical setting. To 
overcome this lower spatial resolution and location uncertainty, several groups investigated the 
complimentary use of DOT along with other conventional imaging techniques. Multiple groups 
have investigated the use of DOT guided by mammogram, US, and MRI [9-11] and demonstrated 
DOT as a promising complementary method to the existing imaging modalities. We have studied 
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the feasibility of using US-guided NIR imaging technique for detecting breast cancer as well as 
monitoring patients who were undergoing Neo-adjuvant chemotherapy [11,12]. 
 In recent years, we have devoted a great deal of time to improve the robustness of the diffuse 
optical tomography in terms of hardware and software [12-14].  In this paper, we are introducing 
a robust and commercially designed ultrasound-guided diffuse optical tomography system which 
is moving this technology one step further in the commercialization and wide use in clinical setting. 
A finite element based calibration method has been introduced to improve the sensitivity of the 
system at different depth and size. The depth and size information has been made available from 
co-registered ultrasound images. The performance of the system was evaluated by solid and blood 
phantoms for absorption, total hemoglobin, and oxygen saturation sensitivity. The system was then 
moved to hospital and used in the clinical study for monitoring patient’s response to neoadjuvant 
chemotherapy. The monitoring results of the first patient are presented in this paper. 
 
4.3. Method 
4.3.1. System Structure 
The miniaturized frequency domain imaging system was designed in order to move the 
ultrasound-guided diffuse optical tomography system one step closer to wide use in clinical setting. 
This system benefits from miniaturized hardware design which reduces the size and improves the 
robustness of the DOT system. The system has four laser diodes of wavelengths 730, 785, 808 and 
830nm as sources to characterize the breast tissue within a near-Infra red range and provide 
oxygenated, deoxygenated, and total hemoglobin concentration inside the breast tissue. These 4 
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laser diodes were sequentially switched by 4 x 1 and 1 x 9 optical switches to 9 source positions 
on the hand-held probe. The reflected light from each source location was received simultaneously 
at 14 parallel detection fibers and passed with fiber bundles to 14 PMT detectors. This system uses 
heterodyne detection channels, at which the light sources were modulated at 140.2MHz and the 
detected signals were mixed with the 140 MHz reference signal. The output of the mixers at each 
channel was further amplified and filtered at 20 kHz. Since we are guiding our DOT with 
ultrasound, a commercial ultrasound array transducer was located in the middle of the probe to 
estimate the approximate depth and size of the lesion. In order to make this system appropriate to 
be used by physicians in the clinical setting, a commercial case has been designed system based 
on hospital safety and standards. For the convenience of the physicians, a moveable arm has been 
added to this system in order to accommodate the touchscreen laptop for controlling data 
acquisition and processing. 
Fig. 4.1. Shows the diagram of the miniaturized system along with the developed system 
which is currently moved to the hospital for clinical studies.  
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Figure 4.1. Block diagram of miniaturized diffuse optical tomography system 
 
4.3.2. Hardware Miniaturization 
In this section, we describe the specific hardware miniaturization and improvements in our new 
system. This system benefits from a miniaturized custom-made laser diode driver which can 
accommodate up to 6 laser diodes, a miniaturized custom-made detection circuit to reduce number 
of unnecessary cables and reduce the size and cost of the detection circuit, and a robust hand-held 
probe which would enable us to connect the DOT system with commercial ultrasound system in 
less than a minute in clinical setting. The details of hardware miniaturization processes are 
described in the following subsections. 
4.3.2.1. Laser Diode Driver and Cooling 
The DOT system has two main blocks as source and detector subsystems. One of the key 
contributing factors in the size of the DOT system in the source subsystem is the light source, its 
50 
 
associated current driver, frequency modulation blocks, and the cooling system. To miniaturize 
the laser diode drivers, a custom-made board is designed in order to reduce the bulkiness and cost 
of light source drivers. In our earlier prototypes, we were using 4 Thorlab’s current driver boards 
which were running each laser diodes. This units were not only costly, they would increase the 
total size of the source subsystem as we had to mount 4 of them inside the source subsystem.  In 
our new system, we have designed a single laser diode board which can accommodate up to 6 laser 
diodes of type A and C. This module can provide a stable feedback controlled DC current for up 
to 200 mA for each laser diode. Since we are modulating our light sources, this module has 6 build 
in bias-tee and a RF input to modulate laser diodes with different RF frequencies. In our system, 
all 4 light sources have been modulated at 140.02 MHz, which provide 4 frequency modulated 
light sources at 4 different wavelengths. The other two laser diode driver ports are not used in our 
current prototype since we are only using 4 wavelengths. Currently we are using four wavelengths 
of 730, 785, 808 and 830 nm in NIR range which are sensitive to oxy and deoxy hemoglobin. The 
output of the lasers is multiplexed via two optical switches from Piezojena co to 9 different 
positions and the light is delivered to the tissue with 9 optical fibers through our hand-held probe.  
Besides the laser diode current driver, we have tried to reduce the size of our laser diodes cooling 
by using pigtailed laser diodes with thermal block from OZ Optics (LDPC-T3). The LDPC-T3 
laser diode assembly has a flat metal surface on the back to attach a thermoelectric cooler (TEC). 
The LDPC-T3 laser diode assembly has a built-in 10 kΩ NTC type thermistor sensor which 
provides feedback for TEC cooler controller. The TCM1000T TEC control module from Thorlabs 
has been used to control current TEC cooler through a Thermal Electric Cooler. The module is 
designed to maintain temperature based on feedback provided from a 10 kΩ NTC type thermistor 
sensor. Temperature is set and monitored using a scaled voltage based on the thermistor resistance 
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for a given temperature, and is available at test points referenced to system ground. In this system 
the TEC drivers have been adjusted to keep the all 4 laser diodes below room temperature at 15 
degrees Celsius.  
 
 
Figure 4.2. Thermal block laser diodes and it’s cooling system for forth-Gen DOT 
 
4.3.2.2. Miniaturized Detection Board 
A custom-made miniaturized detection circuit is designed in order to miniaturize the system in the 
detection subsystem. As this system uses a heterodyne detection system with two very high 
frequency (140MHz and 140.02 MHz), the design need to be robust and precise to prevent any 
high increase in frequency interference and baseline noise. Different scenarios have been tested to 
miniaturize the detection circuit and finally we were able to successfully combine frequency mixer, 
second stage amplifier and the band pass filter together in one miniaturized board to reduce the 
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size of the detection channel. A gain adjustable amplifier is designed for this miniaturized detection 
circuit to provide more freedom in the dynamic range of the system. In the current prototype the 
gains for all 14 channels have been set to 55db. Besides that, a custom-made 20kHz band pass 
filter has been designed to replace the expensive commercial band-pass filter with similar 
performance in terms of baseline noise and filtering quality. 
4.3.2.3. PMT Control with DAC 
In the third gen US-guided DOT I described the use of the FPGA based data acquisition board. 
The miniaturized DAQ can accommodate up to 16 detection channels with two 8 channel A/D 
chip. THE FPGA passes the converted digital signals to a laptop computer through USB port. 
Besides data acquisition, this board is responsible for controlling the optical switches sequence. In 
the new modification on the FPGA based data acquisition board, a port is dedicated to control the 
sensitivity of the photon multiplier tubes.  
 
4.3.3. Light Delivery and Probe Design 
The system has two optical switches which sequentially multiplex the light of 4 laser diodes to 9 
source fibers. These fibers then deliver the light into 9 source positions on our hand-held probe. 
Both optical switches are controlled by the DAQ board and are synchronized with the data 
acquisition. This light is then shined into tissue and the detected signals in the reflection geometry 
was collected at 14 detection location on our probe. The detected light at each detection position 
is then passed to the 14 parallel detection channels. 
The ultrasound probe was located in the center of the probe to localize the lesion. In order 
to use PMT detectors in their maximum dynamic range and prevent the saturation, the very short 
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source- detector distances have been avoided in the system. The 9 sources are located in one side 
of the probe and the 14 detectors are located on the other half of the probe. Fig. 4.3 shows the 
distribution of source and detectors in the combined probe. 
 
Figure 4.3. Combined diffuse optical tomography and ultrasound probe 
 
4.3.4. Software Improvement 
Improvements in robustness and user-friendliness of the software for diffuse optical tomography 
is one of the important steps to move this technology toward wide use in clinical setting. Our 
recent progress on reducing user interaction via automated calibration, outlier removal, data 
selection and lesion boundary detection showed significant improvement in robustness and user-
friendliness of the ultrasound-guided DOT.  To move this technique one step closer to wide use 
in the clinical setting, the presented prototype benefits from a graphical user interface with built-
in automated data selection, outlier removal, lesion boundary detection from ultrasound image 
and image reconstruction.  
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4.4. Phantom Experiments 
Multiple phantom experiments have been designed to evaluate the performance the system. In 
the first sets of experiments, the sensitivity of the system to differentiating high contrast and low 
contrast phantoms has been tested. Two sets of solid phantoms with absorption of 0.12 and 0.23 
cm-1 and same scattering coefficient set at 7-8 cm-1 has been used. To evaluate the sensitivity of 
the system to different size of phantoms, the system has been tested with three different size 
(radius of 0.5, 1 and 1.5 cm) of each high contrast and low contrast phantoms. The phantoms 
were placed in intralipid solution with absorption of 0.02cm-1 and scattering of 7-8 cm-1. The 
Phantoms have been tested at different depths and below table shows the maximum 
reconstructed absorption for each of them. 
 
Table 4.1. Maximum reconstructed absorption map for high contrast and low contrast phantoms. 
phantom radius absorption 
SHC 0.5 cm 0.23 cm-1 
SLC 0.5 cm 0.11 cm-1 
MHC 1 cm 0.23 cm-1 
MLC 1 cm 0.11 cm-1 
LHC 1.5 cm 0.23 cm-1 
LLC 1.5 cm 0.11 cm-1 
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Table 4.2. Maximum reconstructed absorption map for high contrast and low contrast phantoms. 
phantom    
center depth 
SHC SLC MHC MLC LHC LLC 
1 cm 0.146 0.098         
1.5 cm 0.214 0.111 0.152 0.08     
2 cm 0.246 0.083 0.206 0.077 0.148 0.08 
2.5 cm 0.157 0.059 0.253 0.098 0.197 0.079 
3 cm 0.091 0.052 0.227 0.084 0.25 0.09 
3.5 cm 0.077 0.049 0.208 0.078 0.211 0.097 
 
Figure 4.4 shows the stability of the system over time. The experiments have been repeated for 5 
days and the results shows strong stability in the reconstructed absorption over time. The small 
fluctuation of the reconstructed absorption value is related to the experimental errors, including 
minor error in adjusting the phantom at exact depth of 2 cm. 
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Figure 4.4. Maximum reconstructed absorption for small high contrast phantom at depth of 2cm on different 
dates. The reconstructed values at 730,785, 808 and 830nm are presented. The green dashed line represents 
the actual absorption of the phantom. 
 
For later phantom experiment, as Instrumentation Laboratory provides standard Hb 
solution with the total hemoglobin (tHb) concentration similar to that of human and a known SO2 
1, we propose to use this one (Multi-4, Level 2, Instrumentation Laboratory, MA) as the oxy-Hb 
sample. The Multi-4, Level 2 product specification provided by Instrumentation Laboratory is 
tHb=139 g/L, with HbO2 percentage equal to about 97%.  
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Figure 4.5. (a) Glass ball (0.9 cm radius) filled with HbO2 solution and connected to holding fibers. (b) Sketch 
of the testing experimental setup  
 
Next, to evaluate the performance of the system in differentiating oxygenated and 
deoxygenated hemoglobin, the experiment was designed using a hollow glass bulb filled with 
oxygenated and deoxygenated hemoglobin. 
The de-oxygenated hemoglobin (Hb) solution is prepared by adding Na2S2O4 solution 
into the diluted oxygenated hemoglobin (HbO2). 0.05 g Na2S2O4 is solved in 0.5 mL PBS 
solution (with 10 µL mixed solution corresponding to 1 mg Na2S2O4).  We then add the Na2S2O4 
solution into 3.5 mL HbO2 solution to prepare Hb solution. Solution preparation and mixing were 
operated on top of the dry ice to keep the temperature at around 0 °C and slow down the speed of 
de-oxygenated Hb reacting with O2. After sealing the glass ball, we incubated it at around 37 °C 
for 6 min for the Na2S2O4 to work. We calibrated de-oxygenating process with a standard UV-
prob
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phanto
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b a 
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Vis spectrometer (Varian Cary®, Agilent, US). For each ball and Hb solution, the DOT imaging 
procedure was  donein less than 10 minutes. 
The images were reconstructed from measured data and the maximum reconstructed µa 
were compared with the calibrated values with the spectrometer. We used the max reconstructed 
µa to compute SO2. We analyzed the DOT measured SO2 of hemoglobin target at different 
calibrated SO2 (~5-10% and ~97%).   
 
     
Figure 4.6.  Oxygenated and deoxygenated hemoglobin spectrum; a) reconstructed absorption based on 4 
wavelength data with the DOT system. b) measured with spectrometer. 
 
To evaluate the performance of the system in terms of sensitivity to oxygenated and deoxygenated 
hemoglobin, 5 samples of oxygenated hemoglobin and 5 samples of deoxygenated hemoglobin 
has been prepared separately in different dates and each sample was measured with the 
spectrometer and then imaged with the ultrasound-guided DOT system.  Table 4 demonstrates the 
calibrated SO2 level for all 10 samples (5 oxygenated, 5 deoxygenated) with spectrometer along 
with reconstructed SO2 level by using the ultrasound guided DOT system. 
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Table 4.4. Reconstructed oxygen saturation of 100% oxygenated oxyhemoglobin and 0% deoxygenated 
hemoglobin calculated with spectrometer as gold standard and DOT system for 5 different samples. 
 HBO2  HB 
 
Spectrometer DOT system Spectrometer DOT system 
SAMPLE 1 
97.8% 
100% 
6.6% 
7.0% 
SAMPLE 2 
97.5% 
100% 
5.3% 
4.7% 
SAMPLE 3 
97.4% 
98.2% 
13.4% 
5.9% 
SAMPLE 4 
96.7% 
100% 
6.0% 
1.4% 
SAMPLE 5 
97.3% 
94.9% 
4.3% 
22.0% 
 
It can be seen that the DOT system is following the spectrometer results very closely with a slight 
variation. Figure 4.7 shows the comparison of these 5 oxygenated and deoxygenated samples 
calibrated value with the spectrometer and calculated value with DOT system. 
60 
 
  
Figure 4.7. Oxygenated and deoxygenated hemoglobin calibrated with spectrometer and measured with DOT 
system 
 
 
4.5. Finite element calibration 
In order to improve the accuracy of the reconstructed absorption and total hemoglobin 
concentrations, and reduce the sensitivity of the reconstructed value for different depth and size of 
the lesion, a finite element model of the breast has been developed in COMSOL Multiphysics 
(COSMOL Inc, Burlington, MA 01803). The model mimic the breast tissue in ultrasound guided 
imaging technique as a 10cm cylinder with background optical properties of μa =0.02 cm-1 and 
μs’=7cm-1 similar to the average normal breast. The model includes a spherical lesion with 
different sizes and depth to mimic the lesion inside the breast. Figure 10 shows the finite element 
model of the breast which has been used in this study.  
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Figure 4.8. Finite element based cylindrical model of breast using COMSOL. 
 
Since the ultrasound image provides the approximate depth and size of the lesions, we decided to 
use this information in a finite element model to further calibrate our reconstructed absorption 
maps. The model has been used to simulate the forward data for multiple lesions with different 
sizes at different depth.  
Using this model, we have reconstructed multiple lesions with different optical properties 
and size at different depths. By comparing the average of maximum reconstructed absorption of 
each lesion and average of the actual absorption of the lesions, a generalized calibration factor has 
been calculated for each lesion size and depth. Then by using the depth and size information from 
the ultrasound images we were able to calibrate the reconstructed absorption map for each lesion. 
Table 5 shows the maximum reconstructed absorption by using the forward data provided by finite 
element model. In order to decouple the effect of different absorption on the compensation factors, 
for each radius of lesion at each depth, a range of absorption starting at 0.08 cm-1 up to 0.24 cm-
1 have been simulated. 
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Table 4.5. Maximum reconstructed absorption for different lesions with absorption ranging from 0.08-0.24 
cm-1 at different depths. 
Lesion radius: 0.5 cm 
Depth\mua 0.08 cm-1 0.12 cm-1 0.16 cm-1 0.20 cm-1 0.24 cm-1 
1cm 0.0554 0.0837 0.1093 0.1324 0.1532 
1.5cm 0.0711 0.1105 0.1474 0.1817 0.2133 
2cm 0.0772 0.1209 0.1614 0.1988 0.2333 
2.5cm 0.0622 0.096 0.1266 0.1544 0.1796 
3cm 0.0373 0.0559 0.0729 0.0881 0.1016 
3.5 cm 0.0337 0.0537 0.0719 0.0884 0.1034 
Lesion radius: 1 cm 
Depth\mua 0.08 cm-1 0.12 cm-1 0.16 cm-1 0.20 cm-1 0.24 cm-1 
1.5cm 0.0754 0.1116 0.1395 0.1607 0.177 
2cm 0.0958 0.1443 0.183 0.2138 0.2385 
2.5cm 0.0921 0.1355 0.1703 0.1983 0.2211 
3cm 0.0845 0.1218 0.1513 0.1751 0.1947 
3.5cm 0.0884 0.1237 0.1514 0.1736 0.1917 
Lesion radius: 1.5 cm 
Depth\mua 0.08 cm-1 0.12 cm-1 0.16 cm-1 0.20 cm-1 0.24 cm-1 
2cm 0.081 0.113 0.1331 0.1459 0.1544 
2.5cm 0.0859 0.1219 0.1476 0.1662 0.1802 
3cm 0.1036 0.1482 0.1806 0.2048 0.2234 
3.5cm 0.095 0.1342 0.1631 0.1851 0.2023 
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By using each reconstructed value, and comparing it to the real absorption in the model, 
one calibration factor has been extracted. To eliminate the sensitivity of the compensation factor 
to absorption of the lesion, the calibration factors was averaged over different optical absorptions. 
As a result, one number was achieved as the calibration factor for each depth and size of the lesion. 
 
Table 4.6. Calculated calibration factor for different size and depth of the lesion 
 Lesion Radius 
Lesion Depth 0.5 cm 1 cm 1.5 cm 
1cm 1.4981     
1.5cm 1.1050 1.2045   
2cm 1.0106 0.9139 1.2751 
2.5cm 1.2928 0.9788 1.1399 
3cm 2.2485 1.0998 0.9296 
3.5cm 2.2786 1.0977 1.0260 
 
The maximum reconstructed absorption of the high contrast and low contrast balls 
presented in the section 3, has been calibrated using this calibrations factors. The results of the 
calibrated maximum reconstructed absorption have been presented in table 4.7.  
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Table 7. maximum reconstructed absorption for different size of high contrast and low contrast phantoms at 
different depths after calibration with finite element model. 
phantom    
center depth 
SHC SLC MHC MLC LHC LLC 
1 cm 0.178 0.135     
1.5 cm 0.246 0.125 0.201 0.117   
2 cm 0.332 0.139 0.205 0.072 0.136 0.088 
2.5 cm 0.221 0.133 0.285 0.087 0.175 0.087 
3 cm 0.277 0.108 0.293 0.139 0.229 0.112 
3.5 cm 0.233 0.107 0.205 0.144 0.266 0.143 
 
Figure 4.9. compares the average accuracy (%) of the maximum reconstructed absorption 
for different solid high contrast and low contrast phantoms before and after finite element 
calibration. The results show an increase in the average accuracy for different phantom sizes and 
contrasts. 
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Figure 4.9. Maximum reconstruction accuracy (%) for different phantoms before and after finite element 
calibration 
 
4.6. Summary 
In summary, fourth generation of the DOT system has been presented in this chapter. This 
generation of the system benefits from several improvements in terms of hardware and software 
which make it more robust to be used in clinical setting. Besides that, we have worked alongside 
a professional design company to improve the mechanical design and stability of the fourth 
generation DOT system.  
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The system was evaluated by intense phantom experiments and the results have been 
presented and discussed here. Moreover, the new calibration method has been presented based on 
the depth and size information of lesion acquired from the finite element simulation. This 
calibration method uses readily provided information by ultrasound image in terms of depth and 
size of the lesion and calibrate the reconstructed absorption based on that. 
The results presented in this chapter are either published or under publication in multiple journal 
and conference papers as listed in the reference [21,22]. 
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5. Reference Smoothing  
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5.1. Abstract 
Near infrared (NIR) diffuse optical tomography has demonstrated great potential in the initial 
diagnosis of tumor and in the assessment of tumor vasculature response to neoadjuvant 
chemotherapy. To reconstruct the absorption map of a breast lesion, perturbation is needed which 
is the normalized difference between the measurements of lesion-side breast and contralateral 
reference breast. However, the heterogeneity in the reference breast can produce unwanted 
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perturbation which will result in distortion of the reconstructed target absorption map. This cahpter 
introduces a filtering method to overcome the reference heterogeneity. This method corrects 
affected source-detector measurements obtained from the reference side by using averages of 
unaffected measurements. As a result, the filtered perturbation has decreased the effect of 
heterogeneity on the reconstructed absorption maps. To evaluate the performance of this filtering 
method, we have compared the reconstructed results with and without the filtering algorithm using 
simulated heterogeneous reference with heterogeneous absorbers ranging from 0.05 to 0.20 cm-1 
and heterogeneous scatters ranging from 10 to 20cm-1. The results show that the algorithm can 
improve the maximum reconstructed target value up to 99% of the value with homogeneous 
reference. In the worst case of high absorption heterogeneity in reference breast, the maximum 
reconstructed value was around 30.85% of the true absorption without filtering correction and was 
improved to 60.4% of the true absorption value, which is 95% of the reconstructed value when 
using the homogeneous reference.  
 
5.2. Introduction 
Neoadjuvant chemotherapy (NAC) is a frequently used treatment to downstage the disease and 
prepares patients with locally advanced breast cancers for surgery [1]. Different modalities have 
been used to differentiate between patients who respond and who don't respond to NAC; while a 
method which can provide accurate results at early stages of treatment is still under study. Physical 
examination, ultrasound and mammography, conventionally are used to monitor the response of 
patients to NAC and shown moderate results in the assessment of tumor response. In contrast to 
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conventional methods dynamic contrast enhanced MRI shows the ability in early identification of 
nonresponders. This method can predict the presence of residual tumor after completion of each 
NAC which could decrease the patient additional exposure to ineffective and toxic treatments [2]. 
18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography 
(PET/CT) have been reported to show good performance in excluding distant metastases prior to 
neoadjuvant chemotherapy (NAC) treatment [3-5]. Besides these methods, near infrared (NIR) 
diffuse optical tomography also has demonstrated great potential in assessment of tumor 
vasculature response to neoadjuvant chemotherapy [3-5]. MRI and PET equipment are not only 
bulky and expensive, but require the injection of contrast agents. These constraints prevent them 
from being used repeatedly for monitoring patients during treatment. However, near infra-red 
(NIR) systems are portable, require no contrast agents, and have lower cost which make them an 
ideal alternative for repeated use in clinical settings. 
Our group has studied the feasibility of using US-guided NIR imaging technique on patients 
who were undergoing NAC. We assessed them at the pretreatment stage, at the end of every 
treatment cycle, and before surgery. The system used in our study consists of four wavelength laser 
diodes with 740, 780, 808, and 830 nm and ten channels detectors. The laser diodes are connected 
to 4 by 1 switch and 1 by 9 switch. The source fibers and detector fibers are connected to a housing 
probe with commercial US transducer located in the middle. Patients were scanned in a supine 
position and multiple sets of ultrasound images and optical measurements with reflection geometry 
were collected at the lesion location and at a contra-lateral region of the normal breast (reference 
location). The results showed that the initial tumor Hb content was a strong predictor of final 
pathologic response. Besides that, the tHb variation during early treatment cycles can be used to 
predict final pathologic response [4, 5]. 
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Our experiments reveal that using a contralateral reference breast measurement to calculate 
normalized perturbation could reduce the effect of different tissue properties in different patients 
[6]. While using normalized perturbation can improve the consistency and reliability of the results 
between different patients, it is highly dependent on the reference tissue, which is homogeneous 
ideally. However, in clinical setting the reference tissue itself is not completely homogeneous 
which can cause inaccuracy in calculating optical properties and tHb of the tumors. This chapter 
is focused on evaluating the effect of heterogeneous reference breast on the optical properties and 
shape of tumors. 
 
5.3. Method and Model 
In our phantom and clinical experiment procedure, two sets of measurements were collected from 
lesion breast (lesion or target site) and contralateral normal breast (reference site) to calculate 
normalized perturbation as shown below: 
𝑈𝑠𝑐(𝑖) =
𝐴𝑙(𝑖)𝑒𝑥𝑝(𝜑𝑙(𝑖))−𝐴𝑟(𝑖)𝑒𝑥𝑝(𝜑𝑟(𝑖))
𝐴𝑟(𝑖)𝑒𝑥𝑝(𝜑𝑟(𝑖))
                                      (1) 
where  𝐴𝑙(𝑖),𝜑𝑙(𝑖) were measured amplitude and phase for ith source-detector pair from lesion 
breast while𝐴𝑟(𝑖), 𝜑𝑟(𝑖) were measured amplitude and phase for ith source-detector pair from 
reference breast. Heterogeneity in the reference tissue can affect the reference measurements, 
which can cause inaccuracy in normalized perturbation.  Finite-element based method in 
COMSOL Multiphysics (COSMOL Inc, Burlington, MA 01803) was used to simulate the effect 
of heterogeneous reference on the reconstructed NIR image. A 10cm cylinder was modeled as the 
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scattered medium to mimic the breast tissue with optical properties of μa =0.02 cm-1 and μs’=7cm-
1. The ideal reference was homogeneous medium. To model the heterogeneity, a sphere with 
different optical properties was placed inside the reference model. The position, size and optical 
properties of heterogeneity were changed to mimic different scenario of heterogeneous reference 
breasts. Same model was used for the lesion side without the heterogeneous target as shown in 
Figure 1(a), but with a spherical lesion located at center in depth of 2cm with optical properties of 
μa =0.2 cm-1 and μs’=7cm-1. The light was induced to the model from 9-point sources on the top 
of the cylindrical model and the reflected light was collected at 14 different locations on top of the 
cylinder to mimic the 9source positions and 14 detector channels in the hand-held probe. The 
fluence distribution inside the medium when one source was on was shown in Figure 1(b). 
 
 
Figure 5.1. Finite element based cylindrical model of breast using COMSOL. 
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The simulated data at reference side and lesion sides was used to calculate normalized 
perturbation based on formula (1). Optical properties of lesion inside breast were calculated by 
using normalized perturbation and solving inverse problem. 
The simulated data at reference side and lesion sides was used to calculate normalized 
perturbation based on formula (1). Optical properties of lesion inside breast were calculated by 
using normalized perturbation and solving inverse problem. 
𝑈𝑠𝑐 = 𝑊 × 𝛿𝜇𝑎                                                                               (3) 
[𝑚 × 1] =  [𝑚 × 𝑛] × [𝑛 × 1] 
To overcome effect of heterogeneity of modeled reference breast, a filtering method was 
developed. Filtering method was focused on smoothing the reference breast measurements toward 
homogeneous breast tissue measurements. Two different approaches developed to reduce the 
effect of heterogeneity. First approach is based on smoothing the normalized perturbation directly 
while second approach is based on smoothing the heterogeneous reference measurements only. 
First approach (Perturbation Correction): 
Find positive perturbation for each source detector pairs 𝑈𝑠𝑐(𝑖) => 0 
Calculate the average perturbation around that S-D distance by using other measurement data 
                      {∀𝑖 ∈ [1, 𝑚] 𝑖𝑓 𝑈𝑠𝑐(𝑖) > 0|𝑈𝑠𝑐
∗ (𝑖) =
∑ 𝑈𝑠𝑐_𝑅(𝑗)
𝑘
𝑗=1
𝑘
 }                                  (4) 
where 𝑈𝑠𝑐_𝑅 are measurements from SD distance equal to i 
76 
 
Use corrected perturbation to solve the inverse problem and calculate absorption map. 
𝑈𝑠𝑐
∗ = 𝑊 × 𝛿𝜇𝑎                                                             (5) 
[𝑚 × 1] =  [𝑚 × 𝑛] × [𝑛 × 1] 
Second approach (Reference Smoothing): 
Find positive perturbation for each source detector pairs𝑈𝑠𝑐(𝑖) => 0 
Calculate the average reference measurement for S-Ds with similar distance.  
                               {∀𝑖 ∈ [1, 𝑚] 𝑖𝑓 𝑈𝑠𝑐(𝑖) > 0|𝑈𝑟(𝑖) =
∑ 𝑈𝑟_𝑅(𝑗)
𝑘
𝑗=1
𝑘
 }                             (6) 
where 𝑈𝑟_𝑅 are measurements from SD distance equal to i 
 
Smoothing reference based on approximated expected value calculated with other pairs in same 
distance 
𝑈𝑠𝑐
∗ (𝑖) =
𝑈𝑙(𝑖)−𝑈𝑟
∗(𝑖)
𝑈𝑟
∗(𝑖)
                                                               (7) 
Use smoothed reference to solve the inverse problem and calculate absorption map. 
     𝑈𝑠𝑐
∗ = 𝑊 × 𝛿𝜇𝑎                                                             (8) 
[𝑚 × 1] =  [𝑚 × 𝑛] × [𝑛 × 1] 
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5.4. Results 
To evaluate the effect of heterogeneity in reference tissue on perturbation and reconstructed image 
different sets of measurements from different reference and one set of measurement from 
simulated lesion breast have been used to calculate perturbation and reconstruct the image. For the 
sake of brevity, we illustrate the result of 3 cases here, but for all scenarios same trend is observed.  
In first scenario perturbation have been calculated by using homogeneous reference with 
homogeneous background optical properties of μa =0.02 cm-1 and μs’=7cm-1. In the second 
scenario perturbation calculated by using heterogeneous reference with small heterogeneous ball 
with radius of 0.5cm and optical properties of μa =0.02 cm-1 and μs’=7cm-1 in depth of 1 cm. 
Finally, for third scenario an extreme case of heterogeneity have been considered. In this case 
absorption coefficient of small ball in second scenario have been increased to μa =0.2 cm-1.  Figure 
5.2. (a) and (b) shows the normalized perturbation calculated with homogeneous reference while 
Figure 5.2. (c) and (d) shows the real and imaginary parts of normalized perturbation calculated 
with heterogeneous reference of second scenario and Figure 5.2 (e) and (f) shows the real and 
imaginary parts of normalized perturbation calculated with heterogeneous reference of third 
scenario. As shown in Figure 3, all the calculated perturbations are negative both in real and 
imaginary parts when using homogeneous reference, while positive perturbation observed when 
heterogeneous reference from second scenario have been used to calculate normalized 
perturbations. Last row of figure 5.2 shows that by increasing the absorption heterogeneity in 
reference tissue, the number and value of positive perturbation have been increased. 
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Figure 5.2. Real and imaginary part of normalized perturbation a) & b) homogeneous reference breast model, 
c) &d) heterogeneous reference breast model in second scenario, e) &f) heterogeneous reference breast model 
in third scenario. 
 
The Effect of different references on the reconstructed image is illustrated in Figure 5.3. 
Figure 5.3.a shows reconstructed image with normalized perturbation calculated from 
homogeneous reference while 5.3.b and 5.3.c show reconstructed image heterogeneous references 
described in scenario 2 and 3, respectively. Maximum reconstructed value by using homogeneous 
reference was0.1271 cm-1.  By using measurements from modeled reference in second scenario, 
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maximum reconstructed value was changed to 13.06 cm-1 and with measurements from 
heterogeneous reference in third scenario, maximum reconstructed value changed to 0.0617 cm-
1. It can be seen that by changing the amount of heterogeneity shape and maximum reconstructed 
value of lesion has changed. 
 
 
 
 
 
 
 
 
Figure 5. 3. Effect of heterogeneity in the reference breast in the reconstructed image. a) Completely 
homogeneous reference, b) Low absorption heterogeneity inside the reference, c) High absorption heterogeneity 
inside the reference 
 
Both perturbation correction and reference smoothing methods have been applied to the different 
heterogeneous reference. After applying both of these approaches, in all the cases, the 
reconstructed image was improved toward shape and value reconstructed by using homogeneous 
reference. The result of both smoothing algorithms on the worst-case scenario with maximum 
heterogeneity (third scenario) is discussed quantitatively.  
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Figure 5.4. Reconstructed image based on a) Completely homogeneous reference, b) Heterogeneous reference 
before correction, c) Heterogeneous reference after perturbation correction, d) Heterogeneous reference after 
reference smoothing. 
 
Figure 5.4 shows the reconstructed image with homogeneous reference, heterogeneous 
reference without correction, heterogeneous reference with perturbation correction and 
heterogeneous with reference smoothing. As shown in Figure 5.b, the shape and value of lesion by 
using reference of third scenario differ dramatically from the reconstructed image by using 
homogeneous reference in Figure 5.4.a. This heterogeneity caused maximum reconstructed value 
to be less than 48.54% of the maximum reconstructed value with homogeneous reference. By 
applying our reference smoothing and perturbation correction methods, we were able to improve 
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it to 95.04% and 104.48% of reconstructed value with homogeneous reference, respectively. 
Figure 5.c and 5.d shows the reconstructed image with heterogeneous reference of third scenario 
with perturbation correction and reference smoothing, respectively.  
The maximum reconstructed absorption with homogeneous reference, heterogeneous 
reference of third scenario without correction, heterogeneous reference of third scenario with 
perturbation correction and heterogeneous reference of third scenario with reference smoothing 
are shown in table 5.1. 
 
Table5.1. Maximum reconstructed absorption value with homogeneous, heterogeneous and heterogeneous 
after applying perturbation correction and reference smoothing methods 
 
True value 
Homogeneous 
reference 
Heterogeneous 
reference 
perturbation 
correction 
Reference 
smoothing 
µa 0.2 cm-1 0.1271 cm-1 0.0617 cm-1 0.1328 cm-1 0.1208 cm-1 
 
Although the effect of the heterogeneity inside the reference could not be completely 
compensated, it could be reduced by applying these two methods. For example, in the case of high 
heterogeneity inside the reference breast, the maximum reconstructed value shows 51.56% error 
compared to the reconstructed value using homogeneous reference.  
By applying the perturbation correction and reference smoothing methods, this error has 
been reduced to 4.48% and 4.96%, respectively. 
82 
 
 
Figure 5.5. Percentage of maximum reconstructed value with completely homogeneous reference (first column), 
heterogeneous reference (second column), heterogeneous reference after perturbation correction (third 
column) and heterogeneous reference after reference smoothing (fourth column). 
 
This method has been used in multiple clinical cases with wavelength dependency due to 
reference heterogeneity and the results have been improved significantly after using the reference 
smoothing method. Below are the results of one malignant case before and after reference 
smoothing. The results are showing clear increase in the consistency of the reconstructed image 
across multiple wavelengths. 
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Figure 5.6. Reconstructed image of a malignant case before and after reference smoothing method. The left 
column represents the results of 740, 780, 808 and 830 nm before reference smoothing (a-d respectively) and 
right column represents the results of 740, 780, 808 and 830 nm after reference smoothing (e-h respectively) 
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5.5. Discussion 
In this chapter the effect of the heterogeneity inside the reference breast on the perturbation and 
reconstructed absorption map have been studied. The simulation indicates that by increasing the 
heterogeneity inside the reference, the number and value of positive points in perturbation 
increases dramatically. As demonstrated, this change in the perturbation will affect the 
reconstructed absorption map in terms of maximum value, center and shape of the lesion inside 
the target breast. The introduced smoothing methods show promising results to reduce the effect 
of the heterogeneity in the reconstructed image. The application of the method on the clinical 
results showed promising results in terms of improving the robustness of reconstructed absorption 
map. 
This simulation part of this method has been published in a proceeding paper at SPIE 
conference and the completed method along with clinical cases will be further completed and 
submitted separately [7].  
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6.1. Abstract 
Imaging-guided near infrared diffuse optical tomography (DOT) has demonstrated a great 
potential as an adjunct modality for differentiation of malignant and benign breast lesions and for 
monitoring treatment response of breast cancers. However, diffused light measurements are 
sensitive to artifacts caused by outliers and errors in measurements due to probe-tissue coupling, 
patient and probe motions, and tissue heterogeneity.  In general, pre-processing of the 
measurements is needed by experienced users to manually remove these outliers and therefore 
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reduce imaging artifacts.  An automated method of outlier removal, data selection, and filtering 
for diffuse optical tomography is introduced in this chapter. This method consists of multiple steps 
to first combine several datasets collected from the same patient at contralateral normal breast and 
form a single robust reference dataset using statistical tests and linear fitting of the measurements. 
The second step improves the perturbation measurements by filtering out outliers from the lesion 
site measurements using model based analysis. The results of 20 malignant and benign cases show 
similar performance between manual data processing and automated processing and improvement 
in tissue characterization of malignant to benign ratio by about 27%.  
 
 
6.2. Introduction  
According to the American Cancer Society, breast cancer is estimated to be the most common type 
of cancer among women with more than 246000 new cases and approximately 40,000 deaths 
projected in the United States in 2016 [1]. Mammography, ultrasound (US) and magnetic 
resonance imaging (MRI), are widely used to detect and diagnose breast lesions. Mammography 
is the most clinically used imaging modality for breast cancer screening, but it suffers from 
significant limitations such as relatively low sensitivity in early cancer diagnosis, reduced 
sensitivity in women with dense breasts, and low specificity that results in a large number of 
unnecessary biopsies [2].  A new study demonstrates comparable results for breast cancer detection 
rate between US and mammography. However, US still lacks sensitivity and specificity with a 
large number of false positive cases reported [3].  Although MRI has a higher sensitivity in breast 
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cancer detection, the low cancer detection yields in the general screening population and high costs 
of MRI prohibit its applicability as a screening tool [2].  
Diffuse optical tomography (DOT) is a noninvasive functional imaging modality that 
utilizes near-infrared (NIR) light to probe tissue optical properties. Minimal light absorption in the 
NIR wavelength range allows for several centimeters of light penetration in soft tissue such as 
breast and brain and facilitates probing lesions deep in the tissue. Image reconstruction is 
performed using reflected or transmitted light at the tissue surface [4-7]. NIR diffuse optical 
tomography has emerged as a promising modality to detect and monitor functional changes related 
to blood flow and tumor angiogenesis. Using multi-wavelength data acquisition, it is possible to 
quantify tissue characteristics such as oxygenated, deoxygenated, and total hemoglobin (HbO2, 
HbR, and HbT) concentrations as well as hemoglobin oxygen saturation (SO2) and lipid and water 
concentrations [8,9]. Clinical studies of female breasts have demonstrated higher HbT in the 
malignant lesions compared to both healthy tissue and benign lesions [8,10,12,14,15]. 
High sensitivity and cost effectiveness of DOT make it an ideal alternative for conventional 
breast imaging modalities. Currently DOT is not widely used in clinical settings mainly due to the 
low spatial resolution and lesion location uncertainty caused by intense light scattering in soft 
tissue. However, DOT guided by mammography, US, and MRI [10-13] have overcome lesion 
location uncertainty and improved the light quantification accuracy, and have been demonstrated 
as promising complementary methods to the existing imaging modalities. Ultrasound-guided DOT 
system and technique has been developed by our group and clinical results have demonstrated its 
potential in differentiating malignant and benign breast lesions and reducing the need for 
unnecessary benign biopsies [10,15].  In this approach, DOT is used to characterize the US 
detected lesions and to improve the diagnostic accuracy of US by providing complementary optical 
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contrast.  In a recent study, we have demonstrated that when US detection and diagnosis used 
together with optical hemoglobin contrast, the sensitivity of breast cancer detection and diagnosis 
has researched 96.6-100% [10].   
The path toward commercialization of imaging guided DOT techniques depends upon the 
improvement of robustness and user-friendliness of this technique in hardware and software.  
Several groups have investigated various approaches to improve the robustness of the hardware, 
system calibration, data selection, target localization, and image reconstruction [16-20].  Reducing 
user interaction via automated processing of calibration and data selection is an important step 
toward clinical applicability of DOT.   
In US-guided DOT or other hand-held DOT operation, a hand-held probe is placed on top of a 
patient’s breast while the patient is in a supine position [21]. Movements of patient or operator’s 
hand could cause a bad coupling between the light guides and the breast which may result in some 
outliers in measurements.  In other imaging guided DOT approaches, the probe may be fixed, 
however, the bad coupling between tissue and light guides can occur which may result in outlier 
measurements. Additionally, tissue heterogeneity can cause measurement errors at some source-
detector pairs. Recovered background and lesion optical properties highly depend on the boundary 
measurements of light propagating through the tissue underneath and any errors in these 
measurements could cause inaccuracy in fitted background and reconstructed lesion optical 
properties [22,23]. In this study, we introduce an automated outlier removal, data selection, and 
perturbation filtering method for imaging-guided DOT to improve its robustness in breast imaging. 
This method utilizes multiple sets of reference measurements acquired at a normal contralateral 
breast in one imaging session to produce a robust set of reference measurements. Then, the lesion 
measurement set is subtracted and scaled by this robust reference to form the normalized 
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perturbation of the scattered field. Next, the perturbation was filtered for outliers and measurement 
errors based on analysis from simulations.  Finally, the filtered perturbation is used for 
reconstruction of absorption maps and total hemoglobin distributions to characterize malignant 
and benign breast masses. The method of combining multiple measurements to perform statistical 
test for noise and outlier removal and saturation data rejection, can be applied to other methods of 
imaging-guided DOT, such as mammogram or MRI guided diffuse optical tomography with some 
modifications. 
 
6.3. Dataset and System  
6.3.1. Patients 
US-guided DOT is used to characterize 10 malignant and 10 benign lesions of 20 patients. The 
study protocol was approved by the local internal review board (IRB). Signed informed consent 
was obtained from all patients and the study was compliant with the Health Insurance Portability 
and Accountability Act. For each patient, US images and optical measurements were 
simultaneously acquired before biopsy at the lesion site and at the normal contralateral breast of 
the same quadrant as the lesion which is used as reference.  Mammograms, US images before the 
NIR scan were reviewed by attending radiologists and all contralateral measurements were taken 
at normal areas based on the available information [10]. 
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6.3.2. System 
The DOT system used in this study consisted of four laser diodes of wavelengths 740, 780, 808 
and 830 nm. The outputs of the diodes were multiplexed by two optical switches to nine positions 
and were then coupled to a hand-held probe through optical fibers. Ten optical light guides coupled 
diffused light reflected from tissue to 10 photomultiplier tubes. The outputs of the laser diodes 
were amplitude modulated at 140 MHz and the detector outputs were demodulated to 20 kHz. The 
entire data acquisition took approximately 3 to 4 seconds, which was fast enough to repeat several 
times during one imaging session and obtain multiple measurements from each patient at the lesion 
site and the contralateral normal breast at the same quadrant as the lesion, referenced as reference 
measurement in the following text. For each patient, we typically collect 4 to 6 sets of 
measurements from the contralateral breast at slightly different locations. Each set consists of 3 
consecutive measurements which takes around 4 to 5 seconds. The separation between each set of 
measurements varies from few seconds to tens of seconds because of hand-held operation.  
Therefore, a total 12 to 18 measurements may take about one to two minutes. A commercially 
available US transducer located in the middle of the hand-held probe of 9 cm diameter was used 
to acquire US images and optical source fibers and light guides distributed at the periphery were 
used to collect the diffused light from tissue [10]. 
 
6.4. Methods 
Fast data acquisition of US-guided DOT system allows the collection of several datasets during 
one imaging session. The data contains multiple datasets from both lesion and contralateral 
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reference breast.  A novel automated method for outlier removal and data selection is introduced 
to eliminate the effect of inaccurate measurements. The block diagram of the procedures is given 
in Fig. (1).  
 
 
Figure 6.1 Block diagram of the automated outlier removal and data selection method. In the block diagram 
MNR stands for maximum normed residual and IRLS stands for iterative reweighted least square. 
k sets of reference measurements 
Saturated and noise data removal 
IRLS fitting with high residue removal 
Lesion breast measurements Compound reference 
Perturbation filtering 
Data acquisition 
Image reconstruction 
MNR outlier removal 
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Multiple sets of reference measurements were used to form a single high-quality dataset. First, an 
outlier removal procedure is incorporated to eliminate the highly inaccurate measurements with a 
criterion based on the distribution of data collected at each source-detector pair.  Second, a piece-
linear fitting is used to reject the source-detector pair measurements obtained from the saturated 
PMTs. Third, an iterative fitting of residue of the remaining data is calculated to further eliminate 
inaccurate measurements based on the linearity of fitted results of the reference measurements of 
all source-detector pairs. Fourth, a least-square error method is used to form the most accurate 
reference dataset from the remaining measurements. Finally, a perturbation filtering based on 
analysis obtained from the semi-infinite analytical solution of light propagation in tissue [24] is 
utilized to form accurate perturbation set that is more robust to outlier and inaccurate 
measurements. The aforementioned steps are described in detail below. 
 
6.4.1. Outlier Rejection in Reference Measurements 
Each dataset contains measurements from s sources and d detectors with the total number of m=s×d 
measurements. The system used in this study provides 90 source-detector measurements per 
dataset.  A total of k datasets of total k×s×d measurements collected at the reference site were used 
for selecting a best reference dataset. In general, k is in the range of 12 to 18. Since we are using 
a frequency domain DOT system, each dataset consists of amplitude and phase data. The 
maximum normed residual (MNR) is a widely used statistical test to address the problem of outlier 
rejection [25] that has shown outstanding performance in both linear and nonlinear data [26]. The 
MNR test is based on the largest absolute deviation from the sample mean in units of the sample 
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standard deviation. This test is applied to remove outliers for each source-detector pair of total k 
datasets. The outlier measurement is expunged from each source-detector pair dataset based on the 
following criterion. An upper critical value of the t-distribution with k−2 degrees of freedom is 
calculated, and a threshold is obtained based on Eq. (1). 
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    (1) 
In this equation GThreshold(i) is the outlier threshold for ith source-detector pair, tα/(2k), k-2(i) 
denotes the upper critical value of the t-distribution with k−2 degrees of freedom, and α represents 
the level of significance which determines the strictness of outlier removal procedure.  By 
changing this value between 0 and 1, the total number of the outliers and the significance of these 
outliers removed from the database have changed. To find the optimal value of α, the outlier 
removal process is performed for different significance level ranging from 0.01 to 0.5 and the 
optimal value is set to 0.05 based on visual examination of the removed outliers. This optimal 
value is selected in a way that the test only removes the significant outlier data. A G value is 
determined as an absolute deviation of the data point from mean value of the measurements and 
normalized by standard deviation. The data point corresponding to maximum G value which has 
absolute deviation higher than the threshold is considered as an outlier and removed from the 
dataset. The test is iterated until no further outliers are detected beyond the threshold. This test is 
done for both amplitude and phase measurements separately. The details of this method can be 
found in [27,28]. If a data point in either amplitude or phase measurements is considered as an 
outlier, both amplitude and phase measurements are removed from the datasets. 
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6.4.2. Saturation and Noise Data Rejection 
In addition to outliers in the reference measurements, detector saturation is another common 
problem in DOT that can happen as a result of higher light intensity detected at a shorter source 
detector distance.  A semi-infinite analytic solution predicts that the logarithm of the detected 
amplitude for each source-detector pair multiplied by square distance of that specific source-
detector pair, referred as logarithmic amplitude, should linearly decrease with the source-detector 
distance for homogeneous reference measurements. The phase measurement should increase 
linearly with the source-detector distance. A piece-linear fitting method is implemented for the 
amplitude measurements of all remaining source-detector pairs in the reference data after outlier 
rejection.  In general, three sections of shorter source-detector distance, mid-range, and longer 
distance range were used.  If a measured logarithmic amplitude at a shorter source-detector 
distance does not follow the linear profile plotted as a function of the source-detector separation 
in the mid and longer range, we can assume that the PMT is saturated at this detector distance. The 
measurements that fit the linear profile are kept for further processing. Additionally, the phase data 
corresponding to the saturated amplitude data are not reliable and are removed from both reference 
and lesion datasets. 
Besides the saturated measurements which usually happen for the source-detector pairs with 
shorter distances, there are measurements of source-detector pairs with longer distances which are 
dominated by the noise of the system and are not reliable. To improve the dataset, any 
measurements of longer source detector pairs with amplitudes below the electronic noise of the 
system are considered as noisy measurements and expunged from the data. Since the 
corresponding phase data with amplitudes at noise level are not reliable and these data have also 
removed from the data. 
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6.4.3. Iterative Reweighted Least Square Fitting 
The MNR test is based on each source detector measurements separately and it removes the 
outliers at each source-detector pair. At this stage, all remaining datasets after MNR and saturation 
data removal are inputted to an iterative reweighted least square (IRLS) method to obtain an 
accurate linear fit with the minimum fitting residue for both log scaled amplitude and phase 
measurements as functions of source and detector separation. This method has given great results 
in different p-norm minimization problems ranging from compressive sensing to baseline 
correction in industrial settings [29,30]. 
As shown in Eq. (2) IRLS iteratively minimizes the bi-square weighted residual in the 
least-square sense [29]: 
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     (2) 
Here i is the index of the measurement, w is the bi-square weight function, y is the 
measurement value, β includes slope and intercept of the line fitted to the data and f(i,β) is the 
fitted measurement based on the current β . This method reduces the influence of large residuals 
in the fitted reference parameters and improves the fitted results. After the fitting for both 
logarithmic amplitude and phase is completed, the distance of each amplitude and phase 
measurement from the corresponding value on the fitted line of same source-detector distance is 
calculated. All the measurements with higher absolute residue compared to the threshold in either 
amplitude or phase measurements are selected as non-accurate measurements and removed from 
the dataset. The absolute residue threshold of 0.5 has been empirically selected for both amplitude 
and phase based on trial and error from clinical data. Since the IRLS-based minimization is robust 
and less sensitive to noise bursts, it improves the robustness of the dataset selection [30]. 
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6.4.4. Compounded Reference 
Even though accurately fitted lines for both log scaled amplitude and phase are obtained from the 
previous steps, there may still be more than one measurement for each remaining source-detector 
separation. Now one amplitude and one phase measurement per source-detector pair need to be 
selected to form a single robust reference dataset. Here, a least square method is utilized to select 
the measurements with minimum distance from the center of the distribution of remaining 
measurements for each source-detector pair.  This processed is done separately on the remaining 
amplitude and phase data. Therefore, a final reference dataset with high similarity to the fitted 
slope and intercept of outlier removed combination of all the reference datasets is achieved. This 
reference dataset consists of the selected amplitude and phase measurements for the remaining 
source-detector pairs.  This robust set of reference measurements is named as the compounded 
reference and is less sensitive to outliers, PMT saturation and noise. 
To visualize the effect of the proposed process, the amplitudes and phase profiles of one clinical 
case before and after preprocessing, as well as the final compound reference have been illustrated 
in Fig. 6.2. The preprocessing includes, outlier removal, saturation and noise rejection and iterative 
reweighted fitting with higher residue removal. 
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Fig. 6.2. Log scaled amplitude and phase profiles of reference datasets before (first column) and after 
preprocessing (second column) as well as final compound reference (third column). Saturated source-detector 
pairs have been marked with red rectangle in the amplitude part of the first column. 
 
6.4.5. Perturbation filtering 
The procedures described above provide a robust set of reference measurement. For reconstruction 
of lesion absorption map at each wavelength, perturbation is calculated by subtracting the 
compound reference from the lesion data as shown in Eq. (3), in which Al and Ar are amplitude 
and φl and φr are phase of each source-detector pair obtained at the lesion and compound reference, 
respectively.  
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The outliers may present in the perturbation data due to 1) measurements errors caused by 
movements of patient or operator’s hand as well as bad coupling between the light guides and the 
breast; and 2) heterogeneity of the background tissue and the lesion. Lesion measurements are 
expected to be more heterogeneous than the reference measurements because the heterogeneity is 
partially caused by the lesion and partially by the background tissue heterogeneity. Therefore, 
outlier removal procedures applied to reference measurements cannot be implemented to the lesion 
measurements.  Instead, a filtering method is applied to the perturbation based on the constraints 
imposed on the phase difference between the lesion data and the reference data given in Eq. (3). 
These conditions are determined based on the predictions obtained from the semi-infinite 
analytical solution derived from diffusion approximation [24, 31]. Simulations were performed 
using different background optical properties for both reference and lesion breasts as well as 
different optical properties for lesions of different sizes located at different depths [32]. The 
simulations used the same probe geometry and the same number of the sources and detectors as 
the experiments. Table 6.1 shows the range of the parameters used for simulations. The results 
show that the maximum phase difference between lesion and reference measurements of all source 
detector pairs for most scenarios listed in table 1 are in the range of few degrees.   For a 4 cm larger 
lesion of optical contrast of 10 times higher than the background, the maximum phase difference 
is only 22 degrees. This implies that the maximum phase difference of none of the source detector 
pairs can exceed 90 degrees even in extreme cases. This indicates that the cosine term in Eq. (3) 
should always be positive.  Therefore, the real part of the perturbation cannot be less than -1 
assuming that the amplitude measured from lesion Al is smaller than that of the amplitude 
measured at reference Ar due to a higher absorption of the lesion in general. Furthermore, the mean 
and the standard deviation of the imaginary part of the perturbation are calculated. If the imaginary 
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part of a data point is farther than three standard deviations from the mean, it is considered an 
outlier. Any data points in the perturbation that do not meet these two criteria are rejected. This 
step removes outliers in the perturbation likely caused by measurement errors rather than 
heterogeneity of the lesion data.  
 
Table 6.1. Range of parameters used for analytical model and obtained maximum phase delay. 
Background μa Background μ's Lesion Δμa Lesion depth Lesion radius 
0.02 -0.08 (cm-1) 5 – 10 (cm-1) 0.05 – 0.2 (cm-1) 1.5- 3.5 (cm) 0.5-2 (cm) 
 
This normalized perturbation is used for reconstructing the absorption map at each wavelength. 
The total hemoglobin map was calculated from the four wavelength absorption data.  The dual-
zone mesh scheme is used for inversion [32]. Briefly, the imaging volume is segmented into two 
regions consisting of the lesion and the background regions. These two regions are identified by 
the co-registered ultrasound images. This method reduces the total number of voxels with 
unknown optical properties by using smaller mesh size for lesion region and a larger coarse mesh 
size for background. The conjugate gradient method is utilized for iterative optimization of the 
inverse problem. Patient results are calculated from the selected data based on this automated 
outlier removal and data selection procedures. 
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6.5. Results 
To quantify the effectiveness of the proposed method, the results obtained from manually selected 
and processed dataset were compared with the results obtained from the automated data processing 
method. The malignant versus benign classification was based on biopsy result which is the “gold” 
standard in current clinical practice. The manual selection was performed by a trained user to 
obtain the best outlier removal result. The absorption maps obtained at four optical wavelengths 
of benign and malignant examples are shown in Figure 6.3 and 6.4, respectively. The effect of 
outlier and bad measurements on the reconstructed image with no preprocessing is clearly seen 
from the 740 nm image of first row in Fig. 6.4. Both manual and automated methods were able to 
improve wavelength consistency by removing outlier measurements from the dataset. The 
automated method provides similar reconstruction results as the manually processed ones with 
only minor differences. 
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Fig. 6.3. Reconstructed absorption maps of a benign breast lesion obtained at 740, 780, 808 and 830 nm with 
no preprocessing (1st row), with manual data selection (2nd row) and automated data selection (3rd row). Each 
slide is 9 cm by 9 cm reconstructed at the center depth of the lesion. Images from other depths were not shown. 
Vertical bars are absorption in cm-1 unit. 
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Fig. 6.4. Reconstructed absorption maps of a malignant breast lesion at 740, 780, 808 and 830 nm with no 
preprocessing (1st row), with manual data selection (2nd row) and automated data selection (3rd row). Each slide 
is 9 cm by 9 cm reconstructed at the center depth of the lesion. Images from other depths were not shown. 
Vertical bars are absorption in cm-1 unit. 
 
The corresponding ultrasound images and the calculated total hemoglobin maps obtained by both 
manual and automatic methods along with calculated total hemoglobin maps with no outlier 
removal and data selection are presented in Fig. (5) for the benign and malignant cases. The lower 
reconstructed absorption at 740 nm of the malignant case with no data selection caused wavelength 
inconsistency and reduced the calculated total hemoglobin concentration. It can be seen that both 
manual and automated methods have improved wavelength consistency and better malignant to 
benign separation by reducing the effect of saturated, noisy and outlier data. The HbT 
concentrations are also comparable between manual and automated methods. 
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Fig. 6.5. Ultrasound image (1st column) and total hemoglobin map calculated with no data selection (2nd 
column), with manual data selection (3rd column) and automatic data selection (4th column) of the benign (top 
row) and the malignant breast lesion (bottom row) reconstructed with automated data selection method. Each 
slide is 9 cm by 9 cm and vertical bars are hemoglobin concentrations in uM unit. 
 
To compare manual and automated methods statistically, both have applied to the datasets 
collected from 20 patients (10 malignant and 10 benign). The maximum reconstructed absorption 
coefficient with each method was calculated. The mean value and the standard deviation of the 
maximum reconstructed absorption coefficient for malignant and benign groups along with the 
ratio of the mean values are presented in Table 6.2. The proposed automated data selection and 
outlier removal method shows slightly higher malignant to benign ratio of all wavelengths due to 
improved data selection. 
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Table 6.2. Comparison of maximum reconstructed absorption coefficients of malignant and benign groups 
using manual and automated data selection method  
Maximum reconstructed absorption with manual data selection (cm-1) 
  Malignant group Benign group Ratio 
740 nm 0.22 (0.05) 0.11 (0.03) 2.02 
780 nm 0.24 (0.05) 0.13 (0.04) 1.88 
808 nm 0.24 (0.05) 0.14 (0.03) 1.74 
830 nm 0.24 (0.04) 0.12 (0.04) 1.96 
Maximum reconstructed absorption with automatic data selection (cm-1) 
  Malignant group Benign group Ratio 
740 nm 0.209 (0.06) 0.10 (0.03) 2.06 
780 nm 0.22 (0.06) 0.09 (0.03) 2.53 
808 nm 0.23 (0.05) 0.09 (0.03) 2.57 
830 nm 0.24 (0.06) 0.10 (0.03) 2.47 
 
The total hemoglobin concentrations for all 20 patients are calculated using both manual and 
automated data selection methods. Table 3 shows the comparison of the mean and the standard 
deviation of the maximum total hemoglobin concentration reconstructed by both methods as well 
as the ratio of the average HbT concentration between malignant and benign cases. Fig. (6) shows 
the box plots of the reconstructed HbT concentrations of malignant and benign cases. The results 
indicate a slight increase of the malignant to benign ratio of HbT from 2.01 to 2.55 by using the 
automated data selection method.  
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Table 6.3. Comparison of maximum reconstructed absorption coefficients of malignant and benign groups 
using manual and automated data selection method  
Maximum reconstructed total hemoglobin concentration (μM) 
 Malignant group Benign group Ratio 
Manual Data selection 115.38 (20.90) 57.28 (12.38) 2.01 
Automatic Data selection 112.31 (25.06) 43.97 (13.31) 2.55 
 
 
Fig. 6.6. Comparison of maximum total hemoglobin concentration reconstructed with both manual and 
automated data selection methods for 10 malignant and 10 benign cases. Vertical axis is the total hemoglobin 
concentration in μmol/Liter. 
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6.6. Discussion and Summary  
In this chapter an automated pre-processing method for imaging-guided DOT is introduced. This 
method combines multiple datasets obtained from a normal breast which is used as a reference and 
implements outlier and saturation data removal, and linear fitting to form a robust compound set 
of reference measurements.  Because the reference site does not have lesions inside, the location 
of the probe relative to the imaged area is not as critical as lesion site. Therefore, multiple reference 
datasets obtained from slightly different positions can be combined and used as the inputs of the 
automated compound reference selection method. On the other hand, in the affected breast, due to 
the presence of the lesion, the described outlier removal and compound data selection method is 
not appropriate.  Instead, a perturbation filtering method, based on simulations, is introduced to 
eliminate the outliers and inaccurate data due to measurement errors.    
The clinical results using the automated compound reference selection method were 
compared with the manually processed results. An experienced user performed the manual outlier 
removal and data selection after the imaging session and the best manually selected datasets have 
been used for the image reconstruction to compare with the automated method. Although the 
results calculated by our experienced user shows high significance for malignant and benign 
classification, the proposed automated compound outlier removal and data selection method 
outperforms the experienced user without the need for user interactions.  On average, an expert 
need about 15 to 20 minutes to perform the outlier removal and data selection manually, while the 
automated method takes about 20 seconds using a typical dual core computer of 2.3 to 2.8 GHz 
speed.  T-test is performed on the total hemoglobin results obtained from each method and the test 
shows p-values of less than 0.001 in both cases which indicates strong statistical significance 
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between malignant and benign groups. Although both methods provide strong statistical 
significance between malignant and benign groups, but the ratio for malignant to benign has been 
improved with the automated method. In particular, the ratio of malignant to benign lesions has 
been increased from 2.01 using manual data selection to 2.55 using automated data selection 
method with about 27% improvement. 
Although our automated compound data selection method is introduced in the US-guided 
DOT approach, it can be readily applied to other imaging guided DOT approaches.  In general, 
diffuse optical tomography relies on reference measurements either reference data from a normal 
area of the same breast with lesions or a contralateral normal breast. The reference selected from 
a normal area of the same patient is considered the best healthy control because each patient has 
different background tissue optical properties depending on age, tissue composition, and 
menopausal status as reported by several research groups in the past.  Some groups used average 
background tissue by excluding the tumor area in mammography guided or MRI guided diffuse 
optical tomography [12]. Some groups used a localized area of healthy tissue in the lesion breast 
[14] and some including our group used the mirror region in the contralateral breast [8, 10, 15]. 
Depending on the heterogeneity of the healthy tissue, the choice of reference area and the data 
quality of the area impacts the level of tissue contrast. The proposed automated robust reference 
selection method removes data outliers, rejects saturated and noise data, and performs a linear 
fitting if a linear model is used such as approaches using hand-held probes where semi-infinite 
boundary condition is applicable. Thus, the proposed automated reference selection method is 
applicable to these approaches to improve the reference data quality, reduce data processing time. 
This is an important step toward clinical translation and commercialization of diffuse optical 
tomography techniques.   
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In conclusion, an automated compound data selection method is introduced. This method 
forms a compound set of measurements from multiple datasets and outperformed the manual 
method in two different aspects. First, this method is able to eliminate the effect of inaccurate and 
noisy measurements by combining multiple datasets and improves the differentiation between 
malignant and benign cases. The results show improved differentiation between malignant and 
benign lesions compared to the manual data selection. Second, this method makes outlier removal, 
data selection, and processing automated by removing the need for experienced users to perform 
the manual data selection and outlier removal. Utilizing the automated and compound data 
selection method, the data processing speed is significantly improved, and the user dependency of 
data processing is reduced. Future work includes automatic measurements of lesion boundaries in 
US images and input the measurements into image reconstruction. 
The results presented in this chapter was published in journal of biomedical optics express 
and proceeding of OSA conference [32,33]. 
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7.1. Summary 
In this dissertation we have discussed the use of ultrasound-guided diffuse optical tomography 
method to detect breast cancer and monitor patients undergoing neoadjuvant chemotherapy. 
In the first chapter, we have briefly reviewed the history of medical imaging. The field first started 
after discovery of X-rays and its application in imaging the tissue and bones. Several methods and 
modalities for medical imaging has been developed during last century and they have found wide 
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application in disease screening, diagnosis and treatment monitoring. We discussed that, while 
each of the currently used conventional imaging, methods have their strength and drawbacks, the 
need to develop a new imaging technique which could address current needs in medical 
community and improve human health monitoring is being felt more than ever.  
As described in chapter 2, One of the promising ideas for next gen medical imaging devices 
are optical imaging. While several methods of optical imaging with different wavelength sub bands 
are currently under investigation, we discussed the use of near-Infrared light in optical imaging. 
The infrared light has multiple interesting characteristics such as good depth of penetration inside 
the tissue and sensitivity to hemoglobin. In chapter 2, we specifically reviewed near-infrared 
diffuse optical tomography method, followed by description of ultrasound-guided DOT to improve 
the lesion localization and reconstruction accuracy. we have also discussed the use of diffuse 
optical tomography in clinical setting for breast cancer detection. 
In the third chapter, we discussed the development of the third generation of the ultrasound-
guided diffuse optical tomography system and presented the results of clinical studies which have 
been done with that system. we started by reviewing the older two generation of diffuse optical 
tomography and then continued by the details of improvements in the third generation of the 
ultrasound-guided DOT system. we discussed the new compact design, increase number of 
detection channels, improved hand-held probe and improvements in the data acquisition and 
design of the FPGA based data acquisition to reduce the system bulkiness and improve data 
acquisition speed and robustness. Following the system development, we discussed the clinical 
results obtained from one prototype of that system. The total hemoglobin monitoring for a breast 
cancer patient undergoing neoadjuvant chemotherapy has been presented in that chapter. The 
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results show the ability of the third generation of the ultrasound guided DOT system to monitor 
patients undergoing neoadjuvant chemotherapy. 
Chapter 4 was devoted to the development of the fourth generation of our ultrasound 
guided diffuse optical tomography. The improvements in the system in terms of hardware and 
software were discussed. Intensive phantom experiments have been designed and performed to 
evaluate the performance of the fourth generation of the ultrasound guided DOT. The results show 
strong ability of the system in reconstructing optical properties and total hemoglobin concentration 
inside the tissue. Besides the system development an algorithm for calibration of the diffuse optical 
tomography at different depth and sizes have been developed. The results show strong 
improvement in the system sensitivity specially for the deeper targets. 
Besides system robustness and stability, one of the main challenges in the clinical studies 
of the using DOT for breast imaging is the effect of the heterogeneity in the reference 
measurement. In chapter 5 we discussed the effect of reference heterogeneity on the reconstructed 
absorption map. We introduced a smoothing method to reduce the effect of reference heterogeneity 
and measurement inaccuracy in the reconstructed absorption map. The results show strong 
improvement in the value and shape of reconstructed absorption map by use of this method. 
In chapter 6, we introduced an automated algorithm for removing the need for expert user 
to perform data selection and outlier removal.  The discussed algorithm was using multiple 
references and a perturbation filtering to eliminate the outliers in the measurements, make the 
process of data preprocessing automated and form a robust reference measurement to improve the 
accuracy of US-guided DOT. The results of a clinical data show strong improvements in the 
differentiation of the malignant and benign lesion.  
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The results of the developed systems and algorithms in the above in this dissertation was published 
in multiple journal and conference proceedings as listed at the end of this chapter [1-15]. 
 
7.2. Future Works 
By describing all the discussed topics in the previous 6 chapter we covered pretty much the steps 
I took to move the ultrasound guided diffuse optical tomography one step closer to clinical use. 
Although several improvements have been applied to the system development part and improve 
the robustness of the DOT system, there are still several works remaining that one can continue 
upon to increase the performance of the system. In terms of system development one of the first 
steps can be taken is to increase number source wavelengths from four to 6 and incorporate 
wavelengths in the range of 800-900 nm to probe additional chromophores inside the tissue, 
including water and lipid.  
In terms of software improvements, automated detection of the ultrasound boundaries is an 
important step to make this process more robust and less user dependent.  The process of automated 
data selection can be extended to the different lesion measurements as well to improve the accuracy 
of the system.  
One of the main fields that one can improve is the use of ultrasound information in 
differentiating malignant from benign lesions as well as monitoring patients undergoing 
neoadjuvant chemotherapy. As we are currently only using the depth and size of the lesion 
provided by the ultrasound images, looking into ultrasound signals would give us much more data. 
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